bims-barned Biomed News
on BBB and Neurodegeneration-ALS
Issue of 2026–11–15
77 papers selected by
Luca Bolliger, lxBio



  1. Front Immunol. 2026 ;17 1956619
      The gut microbiota contributes to host homeostasis through metabolic, immunological, neural, and barrier-related pathways, and its role in the onset and progression of neurodegenerative diseases has received increasing attention. Patients with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis often exhibit alterations in gut microbial composition, microbial metabolic function, and peripheral inflammatory phenotypes. However, existing clinical evidence is derived predominantly from cross-sectional studies, and the direction of causality between microbiota alterations and disease pathology remains to be established. This review uses a "barrier-immune-glial relay" framework to systematically summarize the potential mechanisms through which gut microbiota-associated signals influence immune homeostasis in the central nervous system. First, alterations in microbial composition, short-chain fatty acids, bile acids, tryptophan derivatives, and lipopolysaccharide may act on the intestinal epithelial barrier, enteric nervous system, and intestinal mucosal immune cells, thereby affecting local immune tolerance and inflammatory responses. Second, intestinal macrophages, dendritic cells, innate lymphoid cells, T cells, and B cells may translate local microbial signals into circulating metabolites, inflammatory mediators, and immune cell-associated signals, which may in turn influence blood-brain barrier function and the central immune microenvironment. Furthermore, microglia and astrocytes, as key integrators within the central nervous system, can respond to gut-derived metabolites and peripheral immune signals. Their interaction network may determine whether neuroinflammation, synaptic injury, and neurodegenerative pathology are amplified or constrained. This review also evaluates the levels of evidence supporting these mechanisms in Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Although these disorders may share mechanistic nodes, including barrier impairment, immunometabolic dysregulation, and glial responses, their core pathologies, immune contexts, and temporal disease trajectories differ substantially. Finally, we propose that establishing a verifiable causal chain linking "microbial functional genes-metabolites-barrier and immune remodeling-glial cell states-neuropathology-clinical phenotypes" will provide a basis for biomarker development and precision interventions in neurodegenerative diseases.
    Keywords:  astrocytes; blood-brain barrier; gut microbiota; gut-immune-brain axis; intestinal mucosal barrier; microglia; neurodegenerative diseases; neuroimmunology
    DOI:  https://doi.org/10.3389/fimmu.2026.1956619
  2. J Clin Med. 2026 Nov 09. pii: 8750. [Epub ahead of print]15(21):
      Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that primarily affects the motor system through the degeneration of motor neurons in the motor cortex, brainstem nuclei, and anterior horn of the spinal cord. ALS typically has a focal onset characterized by muscle weakness, followed by progressive spreading to other body regions, with respiratory muscle failure representing the main life-limiting complication. Median survival is approximately 2-5 years after disease onset. In addition to the well-established motor manifestations, non-motor symptoms are increasingly recognized and may occur in approximately 50% of patients. These include behavioral and neuropsychiatric disturbances, sleep disorders, sensory abnormalities, autonomic dysfunction involving the cardiovascular, gastrointestinal, and genitourinary systems, as well as metabolic and endocrine alterations. Recent evidence supports the concept of ALS as a multisystem disorder characterized by substantial clinical, genetic, and neuropathological heterogeneity. Nevertheless, non-motor manifestations remain less extensively characterized than motor symptoms and are frequently underestimated in clinical practice. This narrative review summarizes the current evidence on non-motor manifestations in ALS, discusses their potential underlying mechanisms and impact on quality of life, and highlights areas requiring further investigation. A better understanding and systematic assessment of these manifestations may contribute to a more comprehensive and patient-centered approach to ALS care.
    Keywords:  amyotrophic lateral sclerosis; cognitive impairment; dysautonomia; multisystem involvement; non-motor symptoms; sleep disorders
    DOI:  https://doi.org/10.3390/jcm15218750
  3. Int J Clin Pharmacol Ther. 2026 Nov 09.
       OBJECTIVES: To investigate whether the modified Bu-Shen-Jian-Pi decoction (mBSJP) is more efficacious than the hitherto used and promoted BSJP formula in the treatment of amyotrophic lateral sclerosis (ALS).
    BACKGROUND: ALS is a fatal neurodegenerative disease with no satisfactory treatment option. Currently, there are few palliative care methods that can significantly delay the progression of the disease, and the efficacy of the herbal treatments used hitherto has also been unsatisfactory.
    MATERIALS AND METHODS: A total of 165 patients with ALS who met the diagnostic criteria after screening were randomly allocated into two groups, a modified Bu-Shen-Jian-Pi decoction group referred to as the mBSJP group and the placebo group. Clinical efficacy and side effects were evaluated during a 16-week observation period. Primary outcomes included Amyotrophic Lateral Sclerosis Symptom Score in Integrative Treatment Scale (ALS-SSIT) and Amyotrophic Lateral Sclerosis Rating Scale-Revised (ALSFRS-R) scores, and secondary observation parameters were 36-Item Short-Form Health Survey Questionnaire (SF-36) and forced vital capacity (FVC).
    RESULTS: A total of 73 patients in the mBSJP group and 71 patients in the placebo group completed the trial. At the end of the 16th week of treatment, there were significant statistical differences observed between the two groups in values for both the ALS-SSIT and the ALSFRS-R scores showing that mBSJP significantly delayed progression of the disease and appearance of symptoms compared to the administration of placebo.
    CONCLUSION: Treatment of ALS with mBSJP delays disease progression and is recommended as a treatment option for ALS in regions where the use of traditional Chinese medicine is regulated and approved.
    DOI:  https://doi.org/10.5414/CP205054
  4. Int J Mol Sci. 2026 Oct 29. pii: 9691. [Epub ahead of print]27(21):
      TAR DNA-binding protein 43 (TDP-43) is the primary pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Yet, despite two decades of intensive research, a reliable peripheral TDP-43 biomarker remains elusive. Recognizing platelets as a major blood reservoir of TDP-43 opens new diagnostic avenues but may also reveal potential vulnerabilities. In this narrative review, we first trace the evolving understanding of TDP-43 from a nuclear RNA-binding protein to a molecule whose functions and disease-associated alterations extend beyond the neuron. We then examine recent breakthroughs demonstrating that TDP-43 function is shaped by its cellular environment and how it may be uniquely concentrated in platelets. Next, we argue that pre-analytical variables, such as hemolysis, clotting, cold-chain failures, and biobank protocols, are not mere "noise" but potential confounders that distort molecular integrity and should be taken into account. Finally, we discuss the biological and methodological uncertainties surrounding platelet TDP-43 and highlight how standardized handling and systematic pre-analytical reporting can improve reproducibility and support future biomarker validation. More broadly, the methodological standards outlined in this review may extend beyond TDP-43 to other disease-related proteins that are present in platelets and similarly sensitive to pre-analytical variability.
    Keywords:  ALS; FTD; TDP-43; biomarker; platelets; pre-analytical quality; proteomodulation
    DOI:  https://doi.org/10.3390/ijms27219691
  5. Neuroepidemiology. 2026 Nov 13. 60(6): 995-1002
       INTRODUCTION: Thyroid disease has been implicated in the pathology of neurodegenerative diseases. However, its role in amyotrophic lateral sclerosis (ALS) is unclear. This study aimed to investigate the association between thyroid disease, including hypothyroidism and hyperthyroidism, and the risk of ALS.
    METHODS: We used a matched cohort design to evaluate UK Biobank data on participants enrolled between 2006 and 2010 who were followed up until 2022. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).
    RESULTS: The study cohort comprised 42,684 patients with thyroid disease (females: 80%). Thyroid disease was moderately associated with an increased risk of ALS development (HR: 1.44, 95% CI: 1.02-2.02), and this association remained similar following adjustment for comparative height at the age of 10 years (HR: 1.44, 95% CI: 1.03-2.03). Hyperthyroidism showed a potential association with an increased risk of ALS development among individuals aged ≤60 years (HR: 21.22, 95% CI: 1.64-274.46) and in females (HR: 3.02, 95% CI: 1.13-8.08).
    CONCLUSION: Our findings demonstrate that thyroid disease is associated with a moderately increased risk of ALS development. Given the multifunctional role of the thyroid gland, further in-depth studies examining the relationship between thyroid conditions and ALS are warranted.
    Keywords:  Amyotrophic lateral sclerosis; Hyperthyroidism; Hypothyroidism; Matched cohort; Thyroid disease
    DOI:  https://doi.org/10.1159/000549662
  6. Int J Mol Sci. 2026 Nov 07. pii: 9993. [Epub ahead of print]27(21):
      Mitochondria are critical for bioenergetics, calcium and redox homeostasis, and apoptosis in neurons. Neurons are especially susceptible to mitochondrial malfunction since they are terminally differentiated and have extraordinary energy requirements. Mechanisms such as defective oxidative phosphorylation, altered fission-fusion dynamics, defective mitophagy, impaired axonal transport and excessive reactive oxygen species (ROS) generation are increasingly appreciated as important mechanisms in major neurodegenerative diseases (NDDs) like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD). The review discusses the structure and function of mitochondria with emphasis on oxidative phosphorylation, ROS and reactive nitrogen species (RNS) signalling, calcium-mediated excitotoxicity, lipid metabolism, and apoptotic and non-apoptotic cell-death mechanisms including necroptosis, ferroptosis, pyroptosis and parthanatos. In particular, disease-specific processes are highlighted, such as impaired mitophagy by amyloid β/tau in AD, PTEN-induced kinase 1 (PINK1)/Parkin dysfunction and complex I inhibition in PD, Superoxide Dismutase 1 (SOD1)/C9orf72-associated mitochondrial defects in ALS, and bioenergetic dysfunction by mutant huntingtin in HD. Therapeutic approaches include mitochondria-targeted antioxidants, fusion and biogenesis enhancers, fission inhibitors, inflammasome modulators, Mitochondrial Permeability Transition Pore (mPTP) inhibitors and gene therapy. Also highlighted are recent advancements such as Ubiquitin-Specific Peptidase 30 (USP30) inhibition, intercellular mitochondrial transfer and regulatory approval of a mitochondria-targeted peptide, together with evidence supporting causality and hurdles underpinning clinical translation. Graded against human-genetic, patient-tissue and model-based evidence, mitochondrial dysfunction is best supported as a primary driver in PD and genetic ALS, and as an early amplifier of proteinopathic or mutant-huntingtin toxicity in sporadic AD and HD.
    Keywords:  mitochondria-targeted antioxidants; mitochondrial dynamics; mitochondrial dysfunction; mitophagy; neurodegeneration; oxidative phosphorylation
    DOI:  https://doi.org/10.3390/ijms27219993
  7. Front Neurol. 2026 ;17 1943566
      Alterations in electromechanical coupling have been described in patients with amyotrophic lateral sclerosis (ALS) and may contribute to the pathophysiology of the disease. Regardless of this, few measurements of electromechanical delay (EMD) in ALS patients have been published. In this motor nerve conduction study, 28 patients with ALS were examined for changes in electromechanical coupling time compared to healthy individuals using sonoelectromyography, a novel dual-method approach combining simultaneous evoked compound muscle action potential (CMAP) recording following an ENG protocol with Doppler ultrasound. In the examination of four muscles (the abductor digiti minimi muscle, brachioradialis muscle, tibialis anterior muscle, and rectus femoris muscle) ALS patients exhibited prolonged electromechanical delay times. These results demonstrate alterations in the electromechanical properties of muscle fibers and provide further insight into muscle contractility in ALS. The findings support the advancement and wider utilisation of sonoelectromyography as an innovative tool for assessing muscle function and indicate that EMD could be incorporated into diagnostic and disease monitoring protocols in ALS.
    Keywords:  amyotrophic lateral sclerosis; distal motor latency; electrodiagnosis; electromechanical coupling; electromechanical delay; mechanical latency; muscle ultrasound; sonoelectromyography
    DOI:  https://doi.org/10.3389/fneur.2026.1943566
  8. Curr Neurovasc Res. 2026 Nov 10.
       INTRODUCTION: Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, are progressive disorders with limited disease-modifying treatments. Poor drug bioavailability, systemic toxicity, and restricted Blood-Brain Barrier (BBB) penetration remain major therapeutic challenges. Although previous reviews have discussed liposomal delivery, an updated mechanistic and translational assessment is needed.
    METHODS: This review analyzed relevant studies on liposome-based drug delivery for neurodegenerative diseases, focusing on BBB penetration, targeting strategies, formulation characteristics, therapeutic mechanisms, and translational challenges.
    RESULTS: Liposomes improve drug solubility, stability, bioavailability, and brain delivery through passive transport, receptor-mediated transcytosis, adsorptive-mediated transport, and ligandassisted targeting. Functionalization with transferrin, lactoferrin, peptides, antibodies, and other ligands can enhance BBB transport and site-specific delivery. Liposomal systems target key pathological mechanisms, including amyloid-β aggregation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and dopaminergic neuronal degeneration. Major gaps include limited clinical validation, long-term safety data, BBB-targeting efficiency, formulation stability, and manufacturing scalability.
    DISCUSSION: Compared with earlier reviews, this review integrates recent advances in liposome engineering with disease-specific mechanisms, BBB-targeting strategies, therapeutic outcomes, and translational barriers, providing a comprehensive perspective on the progression from preclinical development toward clinical application.
    CONCLUSION: Liposomes represent a promising platform for targeted therapy of neurodegenerative diseases. Standardized evaluation, scalable manufacturing, long-term safety assessment, and well-designed clinical trials are essential for establishing their therapeutic efficacy and facilitating clinical translation.
    Keywords:  Alzheimer's disease.; Nanoliposomes; blood-brain barrier; drug delivery; neurodegenerative disease; targeted therapy
    DOI:  https://doi.org/10.2174/0115672026509056261030055920
  9. Sensors (Basel). 2026 Nov 05. pii: 7010. [Epub ahead of print]26(21):
      Neurodegenerative diseases (NDDs), including Parkinson's disease (PARK), Huntington's disease (HUNT), and amyotrophic lateral sclerosis (ALS), are associated with characteristic gait alterations. This study proposes an image-based deep-learning approach for NDD gait classification and its implementation on an edge-computing platform. The main contributions include: (1) mapping synchronized left- and right-foot ground reaction force (GRF) signals from individual gait cycles into a common 2D bilateral force space to generate three complementary representations-Trajectory Map (bilateral force trajectories), Derivative Map (dynamic transitions), and Occupancy Heatmap (loading-state distributions); (2) adapting ImageNet-pretrained MobileNetV2 to four-class gait classification (CONTROL, ALS, HUNT, and PARK) through classification-layer retraining and feature-extractor fine-tuning; (3) comparing compact (α = 0.35; ~0.4 M parameters) and higher-capacity (α = 1.4; ~4.4 M parameters) MobileNetV2 configurations; and (4) evaluating the deployment of the resulting models on a Raspberry Pi 4 as a resource-constrained edge-computing platform. The models were evaluated on a test subset of 2259 gait cycles from the Gait in Neurodegenerative Disease Database, comprising CONTROL (612), ALS (367), HUNT (727), and PARK (553). Fine-tuning increased overall four-class accuracy from 89.64-92.61% to 95.09-96.41% across the GRF representations and model configurations. Paired comparisons showed improvements of 3.81-6.29 percentage points across all six matched configurations. Class-specific one-vs-rest accuracy was consistently high after fine-tuning: CONTROL (97.74-98.63%), ALS (98.41-98.94%), HUNT (96.02-97.21%), and PARK (97.30-98.23%). The highest four-class accuracy (96.41%; 95% CI: 95.45-97.29%; Occupancy Heatmap, α = 1.4) was preserved for the unquantized TFLite model evaluated on the Raspberry Pi 4, while dynamic-range quantization reduced accuracy by 0.22 percentage points to 96.19%. Compact fine-tuned MobileNetV2 models required approximately 42-46 ms of inference latency and 89-97 mJ of estimated incremental energy per inference, compared with 324-374 ms and 680-785 mJ, respectively, for the higher-capacity models. Dynamic-range quantization reduced model storage by approximately 62% (α = 0.35) and 72% (α = 1.4). Overall, bilateral GRF representations combined with MobileNetV2 transfer learning enable accurate multiclass NDD gait classification, while compact models provide a favorable performance-efficiency trade-off for resource-constrained edge implementation. However, subject-independent validation remains necessary because the reported accuracy was obtained using gait-cycle-level data partitioning.
    Keywords:  Huntington’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; deep learning; edge computing; embedded systems; gait classification; image processing; neurodegenerative diseases; vertical ground reaction force
    DOI:  https://doi.org/10.3390/s26217010
  10. Int J Mol Sci. 2026 Oct 28. pii: 9632. [Epub ahead of print]27(21):
      Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder whose genetic architecture and molecular mechanisms remain incompletely understood, particularly in sporadic disease. To investigate whether genetically regulated DNA methylation may help interpret ALS susceptibility, we conducted a methylome-wide association study of genetically predicted blood methylation using the PrediXcan framework. CpG-specific models from the ARIES and Understanding Society cohorts were applied to ALS genome-wide association study (GWAS) summary statistics from 27,205 cases and 110,881 controls of European ancestry. Using S-PrediXcan, we evaluated 192,378 unique CpG sites. At nominal p < 0.05, 3741 CpGs were associated with ALS risk using ARIES models and 13,127 using Understanding Society models. After Bonferroni correction, 25 CpGs across eight genomic regions remained significant, including signals near established ALS and ALS-frontotemporal dementia loci (C9orf72, TBK1, SCFD1, and MOB3B). Three CpGs mapped to WHAMM at 15q25.2, a region not previously implicated by ALS GWAS. Predicted methylation was positively associated with risk at 18 CpGs and inversely associated at seven. Complementary whole-blood transcriptome-wide association analysis identified 11 significant genes, including C9orf72. Together, these findings prioritize regulatory candidates for functional investigation without establishing that methylation changes cause ALS.
    Keywords:  amyotrophic lateral sclerosis; epigenetics; genetic regulation; methylome-wide association study; transcriptome-wide association study
    DOI:  https://doi.org/10.3390/ijms27219632
  11. Front Cell Neurosci. 2026 ;20 1911064
      Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by motor neuron degeneration. Several genetic risk factors, including mutations in C9orf72, SOD1, TARDBP and FUS have been linked to disease. However, the precise cellular pathogenic mechanisms of ALS remain poorly understood, impeding the development of effective therapeutics. ALS model systems, ranging from Drosophila, mice to human induced pluripotent stem cells (hiPSCs), are powerful research platforms for decoding these mechanisms, with their high genetic tractability allowing for the tracking of disease across the life course. Recently, the application of single cell resolution approaches have allowed the dissection of the heterogenous nature of cellular response to disease in these models, revealing novel ALS pathogenic mechanisms and therapeutic targets. In this Review, we explore the unique benefits and challenges of using single-cell RNA-sequencing (scRNA-seq)/single-nucleus RNA-sequencing (snRNA-seq) analysis of in vivo and in vitro ALS model systems to identify disease pathways and drive our mechanistic understanding of ALS forward. By using single cell approaches in models of ALS, researchers can identify novel, druggable, cellular pathways acting across all disease stages that may be obscured in late-stage post-mortem tissue.
    Keywords:  ALS; C9; Drosophila; TDP43; model systems; repeat expansion; single cell RNA-sequencing
    DOI:  https://doi.org/10.3389/fncel.2026.1911064
  12. Anim Cells Syst (Seoul). 2026 ;30(1): 644-656
      Mitochondrial dysfunction and impaired mitophagy are increasingly recognized as central contributors to pathogenesis of amyotrophic lateral sclerosis (ALS). In this study, we identified OGS-MA114 (C₂₃H₁₉ClN₄O₃S), as a compound that activates mitophagy through a bioactive chemical library screen in SH-SY5Y cells. OGS-MA114 significantly enhanced autophagic and mitophagic flux, increased Ser65-phosphorylated ubiquitin levels, and promoted Parkin recruitment to damaged mitochondria, indicating activation of the PINK1/Parkin pathway. In SH-SY5Y cells expressing the ALS-associated FUSP525L mutant, OGS-MA114 restored mitochondrial membrane potential, reduced cleaved caspase-3 levels, and improved cell viability under mitochondrial stress conditions. Furthermore, in a transgenic zebrafish model expressing mutant FUSR521C, OGS-MA114 significantly improved locomotor activity and survival while reducing cell death in the spinal cord. These findings suggest that OGS-MA114 ameliorates ALS-associated pathological phenotypes by enhancing PINK1-dependent mitophagy. Thus, pharmacological modulation of mitophagy may provide a useful basis for further investigation of ALS and -related neurodegenerative disorders.
    Keywords:  FUSP525L; OGS-MA114; amyotrophic lateral sclerosis; mitophagy; neuroprotection
    DOI:  https://doi.org/10.1080/19768354.2026.2736980
  13. Neuroimaging Clin N Am. 2027 Feb;pii: S1052-5149(26)00073-0. [Epub ahead of print]37(1): 103-123
      Movement disorders encompass a wide variety of neurodegenerative conditions that ultimately present with a combination of changes in movement, and in some cases, changes in cognition. The heterogeneity of movement disorders reflects several underlying pathologic processes and include relatively common entities, such as Parkinson's disease and normal pressure hydrocephalus, as well as less common entities, such as atypical Parkinsonian syndromes, Huntington's disease, Wilson's disease, and amyotrophic lateral sclerosis. Multimodal imaging techniques, including a variety of PET radiotracers, can facilitate an accurate diagnosis of neurodegenerative movement disorders, highlighting the critical role of radiologists in this field.
    Keywords:  Amyotrophic lateral sclerosis; Atypical Parkinsonian syndromes; Huntington disease; Movement disorders; Neurodegenerative disease; Parkinson disease
    DOI:  https://doi.org/10.1016/j.nic.2026.07.006
  14. Mol Syst Des Eng. 2026 Nov 03.
      The blood-brain barrier (BBB) is a selectively permeable border that regulates the transport of chemical compounds into and out of the central nervous system (CNS). To discover medicinal drugs that can target the CNS, we must be able to efficiently screen pools of potential candidate CNS-targeting drugs to identify those that can permeate the BBB. However, drugs that readily permeate the BBB are comparatively rare, thus CNS drug discovery typically requires screening very large candidate libraries. In the last two decades, a diverse portfolio of machine learning models has been developed to predict the permeability of the BBB. However, many of the most accurate models reported to date do not scale well to large screenings, because they depend on high-cost descriptor pipelines and/or computationally intensive model architectures. In this work, we used a straightforward, computationally efficient set of descriptors in conjunction with a lightweight random forest model to perform a large-scale screening for BBB permeable drugs. Specifically, we predicted the propensity to cross the BBB for roughly 117 million compounds from PubChem. The screen ran on CPU-only hardware (64 cores) and completed in less than 800 CPU hours; the main resource constraint was memory, with ∼4 TB RAM required for data handling. From these predictions, we prioritised a small set of top-ranked compounds and used well-tempered metadynamics with lipid-bilayer proxies to assess whether their membrane-crossing barriers were consistent with the model-predicted permeability classes. We hope that similar workflows can be adopted in the near term to improve the throughput of BBB-permeability prioritisation in drug discovery.
    DOI:  https://doi.org/10.1039/d6me00041j
  15. Curr Pharm Biotechnol. 2026 Nov 03.
      Ferroptosis is an iron-mediated form of programmed cell death characterised by distinct features, including excessive iron accumulation, lipid peroxidation, and impaired antioxidant mechanisms. The susceptibility of the Central Nervous System (CNS) to ferroptosis has been reported, along with evidence that ferroptosis is associated with neurological disorders such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), stroke, and Multiple Sclerosis (MS). To date, major ferroptosis inhibitors encompass iron chelators, lipid-trapping antioxidants, and antioxidant modulators. Translational challenges in drug toxicity, selectivity, and delivery promote drug development in terms of improving pharmacokinetics through structural modification, alternative routes of administration, and nanoparticle encapsulation. In addition, research on identifying novel and promising ferroptosis inhibitors from natural products and known drug compounds is continuous, accompanied by ongoing drug optimisation and modification. Biomarkers of ferroptosis have been discussed given the emerging clinical interest in them for disease diagnosis or prognosis and patient stratification. Standalone anti-ferroptotic treatments for CNS disorders have been found to be difficult to achieve favourable clinical outcomes, thereby suggesting combination therapies that not only harness ferroptosis but also address diverse pathological pathways in the respective diseases as a prospect for managing CNS disorders. Thus, this article aims to review recent updates on clinically approved ferroptosis inhibitors as well as summarise the current drug development landscape and outline future directions to provide a better understanding of the contemporary development of ferroptosis inhibitors for neurological disorders.
    Keywords:  Alzheimer’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; iron metabolism; lipid peroxidation; multiple sclerosis; programmed cell death
    DOI:  https://doi.org/10.2174/0113892010520055261019113815
  16. Fluids Barriers CNS. 2026 Aug 14. pii: 125. [Epub ahead of print]23(1):
      The blood-brain barrier (BBB) functions as a highly selective regulatory system governing molecular transport between systemic circulation and the central nervous system. The maintenance of this strict permeability relies on the continuous, high-energy interactions of the neurovascular unit (NVU) primarily fueled by mitochondria. Sustaining the electrochemical gradients and active transport systems essential for this regulation imposes an immense metabolic burden, rendering the NVU uniquely susceptible to bioenergetic failure. This review critically evaluates the mechanistic link between mitochondrial dysfunction and specific, aberrant BBB phenotypes. We detail evidence surmising how mitochondrial dynamics within multiple NVU cell populations, including brain microvascular endothelial cells, pericytes, astrocytes and microglia, govern barrier stability. We specifically examine how mitochondrial reactive oxygen species (mtROS), aberrant fission/fusion cycles and impaired quality control precipitate tight junction disassembly and inflammatory activation. Furthermore, we explore the emerging paradigm of "mitoceuticals," a class of therapeutics engineered to correct these bioenergetic deficits. By targeting molecular mechanisms such as mitoNEET stability and mitochondrial dynamics, these agents offer a unique strategic opportunity to preserve NVU function. We conclude by evaluating the potential of these agents to therapeutically reinforce the bioenergetic infrastructure of the NVU as a vital, yet under-explored, avenue for treating ischemic and neurodegenerative disorders.
    Keywords:  Astrocytes; Bioenergetics; Endothelial cells; Ferroptosis; Microglia; Mitochondria; Neurovascular unit; Oxidative stress; Pericytes; Tight junctions
    DOI:  https://doi.org/10.1186/s12987-026-00854-x
  17. Diagnostics (Basel). 2026 Oct 30. pii: 3589. [Epub ahead of print]16(21):
      Lipids constitute nearly half of the brain's dry weight and play a crucial role in maintaining the function of the central nervous system (CNS). Beyond their well-known function as structural components of cellular membranes and energy storage, lipids are now identified as dynamic bioactive mediators that regulate neuronal signaling, synaptic plasticity, membrane integrity and neuroinflammatory responses. Emerging evidence demonstrates that altered lipid homeostasis is associated with the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD). In this review, we highlight key pathophysiological mechanisms, including dysregulation of lipid transport by cholesterol and apolipoprotein E4 (ApoE4), which may influence the aggregation of amyloid-β in AD. We discuss sphingolipid dysregulation and impaired glucocerebrosidase activity in modulating α-synuclein pathology in PD. Furthermore, we emphasize the importance of polyunsaturated fatty acids (PUFAs) and their oxidized forms in the regulation of oxidative stress, ferroptosis, and neuronal cell death in ALS and HD. Besides mechanistic information, this review also highlights the recent advancements in modern lipidomic technologies, such as high-resolution mass spectrometry and multi-omics integration, which have facilitated the comprehensive characterization of disease-associated lipid alterations. Emerging lipid signatures, including alterations in ceramide, cholesterol metabolism and lipid droplet biogenesis in glial cells, are being investigated as candidate biomarkers and therapeutic targets. Collectively, we outline a strategy for exploiting the brain lipidome to explore the potential for personalized disease-modifying strategies against neurodegeneration by integrating mechanistic, diagnostic and therapeutic insights.
    Keywords:  Alzheimer’s disease; Parkinson’s disease; biomarkers; lipid metabolism; lipidomics; neurodegeneration; neuroinflammation; precision medicine
    DOI:  https://doi.org/10.3390/diagnostics16213589
  18. J Pharmacol Sci. 2026 Dec;pii: S1347-8613(26)00060-5. [Epub ahead of print]162(4): 331-345
       BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with complex pathogenic mechanisms, and the efficacy of single-target interventions remains limited. γ-Oryzanol (Orz) and α-lipoic acid (ALA) exert neuroprotective effects individually, yet their combined effects and molecular mechanisms in ALS remain unclear.
    AIM: To investigate the therapeutic effects and mechanisms of combined Orz and ALA treatment in ALS.
    METHODS: Network pharmacology was used to identify potential targets shared by the compounds and ALS. Core targets and pathways were identified through protein-protein interaction (PPI) network analysis, molecular docking, and functional enrichment analysis, followed by experimental validation in hSOD1G93A cell and transgenic mouse models.
    RESULTS: Six core targets (EGFR, AKT1, HSP90AA1, BCL2, SRC, HSP90AB1) were identified. In hSOD1G93A cells, combined treatment modulated mRNA expression and protein phosphorylation of the core targets and attenuated cellular injury. In hSOD1G93A transgenic mice, the combination delayed disease progression, prolonged survival, improved motor function, and reduced motor neuron loss. This combination alleviated inflammation and apoptosis by activating the AKT/GSK3β pathway.
    CONCLUSION: Combined Orz and ALA treatment modulates core targets, activates the AKT/GSK3β pathway, and suppresses inflammation and apoptosis. This combination represents a promising therapeutic strategy for ALS.
    Keywords:  AKT/GSK3β pathway; Amyotrophic lateral sclerosis; Apoptosis; Combined therapy; Inflammation
    DOI:  https://doi.org/10.1016/j.jphs.2026.10.004
  19. BMC Med Genomics. 2026 Aug 18. pii: 176. [Epub ahead of print]19(1):
       BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motor neuron degeneration, while primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with prominent immune dysregulation. Although immune-related alterations have been implicated in ALS and autoimmune diseases, the clinical coexistence of ALS and pSS remains poorly characterized. We aimed to describe the clinical features of patients with concomitant ALS and pSS and to explore peripheral blood transcriptomic patterns in independent ALS and pSS cohorts.
    METHODS: We retrospectively identified patients with both ALS and pSS through systematic electronic health record screening and multidisciplinary clinical review. Clinical characteristics, disease chronology, treatment exposure, and outcomes were summarized. In parallel, we performed an exploratory transcriptomic analysis using publicly available peripheral blood datasets from independent ALS and pSS cohorts. Differentially expressed genes and overlapping inflammatory signatures were evaluated, with additional sensitivity assessment performed using an independent ALS cohort.
    RESULTS: Seven patients fulfilling diagnostic criteria for both ALS and pSS were identified. The temporal relationship between the two diseases was heterogeneous, with variable disease onset sequences and clinical trajectories. Immunomodulatory treatments were associated with transient improvement in systemic autoimmune manifestations in some patients, but no conclusions regarding modification of ALS progression could be established. Transcriptomic analyses identified overlapping upregulated genes between ALS and pSS cohorts, enriched in interferon- and NF-κB-related inflammatory signatures. However, these signatures represent commonly observed inflammatory responses across multiple disease contexts and should not be interpreted as evidence of ALS-pSS-specific biological convergence. Sensitivity assessment using an independent ALS cohort demonstrated partial reproducibility of selected non-specific inflammatory signatures across datasets.
    CONCLUSIONS: Taken together, these findings present two independent, exploratory observations: a rare clinical co-occurrence and a non-specific systemic inflammatory signature identified in unrelated public datasets, both requiring sensitivity assessment and serving as hypothesis-generating baselines for future studies.
    Keywords:  Amyotrophic lateral sclerosis; Case series; Inflammatory signature; Peripheral blood transcriptomics; Primary Sjögren's syndrome
    DOI:  https://doi.org/10.1186/s12920-026-02456-w
  20. Cell Death Discov. 2026 Aug 14. pii: 451. [Epub ahead of print]12(1):
      Mutations in Fused in Sarcoma (FUS), an RNA binding protein, cause Amyotrophic Lateral Sclerosis (ALS). ALS is an aggressive neurodegenerative disease resulting in motor neuron degeneration. Defects in synaptic integrity precede neuronal loss in ALS, but the mechanisms responsible for these early synaptic defects are unclear. To investigate early synaptic defects associated with ALS, we expressed an ALS-linked variant of human FUS in adult motor neurons and assessed synaptic pathology at the neuromuscular junction (NMJ). Here, we highlight the accumulation of FUS-positive aggregates at synaptic terminals and subsequent reduction in microtubule stability. Autophagy induction via expression of Rab1 or Fragile-X Mental Retardation Protein 1 (FMR1), or treatment with rapamycin reduces aggregate formation and restores synaptic structure and function. These findings reveal the utility of inducing autophagy to address early synaptic dysfunction in an ALS model and demonstrate a potential therapeutic target to preventing later stages of disease progression.Teaser Maintaining synaptic integrity protects motor neurons in a model of ALS.
    DOI:  https://doi.org/10.1038/s41420-026-03286-6
  21. Stem Cells. 2026 Nov 13. pii: sxag064. [Epub ahead of print]
      Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterised by progressive loss of upper and lower motor neurons (MNs), with limited therapeutic options and modest benefit from currently approved drugs. Induced pluripotent stem cells (iPSCs) have emerged as a versatile platform for ALS research, enabling both regenerative medicine and phenotypic drug screening. iPSC-based transplantation strategies aim to replace lost cells or deliver neuroprotective support, while iPSC-derived MNs support drug discovery and repositioning. In the two decades since their discovery, iPSC technologies have progressed from concept to clinical translation, with both cell therapy products such as AstroRx and XS-228 entering trials and three screened drug candidates, Ropinirole, Bosutinib, and Ezogabine, advancing into clinical trials, underscoring their translational potential. In this review, we summarise iPSC-based approaches to ALS, focusing on cell therapies and drug discovery, highlight factors influencing transplantation success, and discuss ongoing clinical trials. We further discuss constraints that impede clinical trial progress, including limited understanding of ALS pathogenesis, absence of robust biomarkers to guide patient stratification and evaluate treatment response, and technical challenges related to the maturation of iPSC-derived neural cells. Finally, we advocate that advancing iPSC approaches requires both deeper understanding of ALS biology and technical innovation. Key priorities are refining iPSC differentiation protocols to improve neuronal maturity and implementing trial designs with adequate duration and rigorous patient stratification.
    DOI:  https://doi.org/10.1093/stmcls/sxag064
  22. iScience. 2026 Nov 20. 29(11): 118073
      Brain-computer interface (BCI) technology serves as an important bridge between the nervous system and external devices and has shown considerable promise for the diagnosis and treatment of neurodegenerative diseases, whose global burden continues to increase: in 2021, more than 57 million people were living with dementia worldwide, with Alzheimer's disease (AD) accounting for approximately 60-70% of cases, while an estimated 11.77 million people were living with Parkinson's disease (PD) in 2021, according to the Global Burden of Disease Study 2021. This growing disease burden, together with the progressive loss of cognitive, motor, and communicative functions, highlights the need for more precise approaches to early detection, functional assistance, and individualized intervention. Conventional diagnostic and therapeutic approaches remain poorly suited to early detection and timely intervention. This paper analyzes the development of BCI technology, from the first detection of electroencephalogram (EEG) signals to the parallel development of invasive and non-invasive systems, and outlines the basic principles of signal acquisition, processing, and decoding, together with the relative advantages and limitations of different approaches. It then focuses on the use of BCI in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), covering early diagnosis, functional reconstruction, and neuromodulation. The article also discusses the difficulties encountered by BCI technology in terms of technological realization, clinical translation, and ethical considerations, as well as several future research directions, including multimodal fusion, adaptive algorithms, closed-loop control systems, and personalized treatment so as to drive the applications of BCI in precision medicine and in neurological diseases.
    Keywords:  BCI; brain-computer interface; closed-loop regulation; neurodegenerative diseases; neuroplasticity; precision medicine
    DOI:  https://doi.org/10.1016/j.isci.2026.118073
  23. Cells. 2026 Nov 03. pii: 2003. [Epub ahead of print]15(21):
      Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease hallmarked by progressive loss of neuromuscular junctions, cortical and spinal motor neurons (MNs), resulting in muscle paralysis. MNs are particularly vulnerable due to their long axons and high metabolic demands. ALS pathology involves impaired RNA metabolism, protein aggregation, cytoskeletal defects affecting organelle trafficking, and mitochondrial dysfunction, ultimately leading to neurodegeneration. Current treatments only marginally extend survival, calling for alternative therapies. We recently reported beneficial effects of electromagnetic alternating field stimulation (ACMS) on axonal regeneration and organelle motility in ALS. Here, we used iPSC-derived spinal MNs from familial ALS patients with FUS mutations to optimize magnetic field parameters regarding frequency, amplitude and duration. Using compartmentalized neuron cultures, we also tested different magnetic field orientations relative to axons. Following ACMS, we assessed axonal organelle trafficking and the nuclear DNA damage response (DDR) by live-cell imaging. Untreated ALS neurons showed clear defects in both assays. Exposure to magnetic AC sine waves above a threshold amplitude of 7 mT, applied perpendicular to the axonal plane with an optimal low frequency of 25 Hz, led to a sustained boost of mitochondrial and lysosomal motility for over one week and rehabilitation of DDR. These phenotypic improvements correlated with global transcriptomic changes revealed by RNA-sequencing. These phenotypic improvements correlated with global transcriptomic changes revealed by RNA-sequencing. While untreated mutant and wild-type neurons displayed different gene expression profiles, ACMS converged them to a novel, harmonized transcriptional state across all lines. Further analysis of differentially expressed genes (DEGs) yielded a conceptual model in which ACMS activates extracellular matrix (ECM)-mediated cell adhesion and neurotransmitter receptor, ion channel and kinase signaling pathways, ultimately modulating gene transcription and, thereby, motor- and microtubule-associated proteins. This model provides a framework for follow-up studies to experimentally validate the underlying mechanisms and assess the therapeutic potential of ACMS as an alternative biophysical treatment modality for neurodegenerative diseases.
    Keywords:  DNA damage response; Lou Gehrig’s disease; axonal organelle motility; extracellular matrix; global RNA-seq; inducible pluripotent stem cells; magnetic-field-mediated neuroprotection; motor neurons; neurodegenerative disease
    DOI:  https://doi.org/10.3390/cells15212003
  24. Brain. 2026 Nov 11. pii: awag391. [Epub ahead of print]
      The clinical heterogeneity of Amyotrophic Lateral Sclerosis (ALS) remains a fundamental barrier to effective therapy. While cell cycle re-entry in post-mitotic neurons is a known precursor to neurodegeneration, its role in defining patient-specific outcomes has never been established. Here, we integrate large-scale transcriptomic profiling from the AnswerALS cohort with mechanistic studies in human iPSC-derived spinal motor neurons to define how cell-cycle re-entry shapes disease heterogeneity in ALS. We identify a transcriptionally distinct patient subgroup with the highest expression of G1 or G2-phase cyclins that exhibit significantly slower functional decline (ALSFRS-R), whereas the engagement of S-phase markers correlates with accelerated disease progression. Nucleocytoplasmic transport dysfunction, a hallmark of ALS and related disorders, disrupts the spatial distribution of key regulatory proteins and may contribute to maladaptive cell-cycle activation. Our recent evidence suggests that impaired nuclear import may initiate, rather than merely accompany, neuronal cell-cycle re-entry. Using iPSC-derived motor neurons, we show that impaired nuclear import initiates TDP-43 pathology and global nuclear/cytoplasmic mis-localization of key ALS-related proteins. This nucleocytoplasmic transport dysfunction triggers a transient wave of cell-cycle activity immediately preceding neuronal cell death. Crucially, we show that DNA-replication initiation is a pathological inflection point of no return, as neurons entering S-phase accumulate replication-associated DNA damage and undergo cell death. Selective inhibition of CDK4/6 prevents S-phase entry and confers potent neuroprotection. Our findings demonstrate that impaired nuclear import drives maladaptive cell-cycle reactivation in ALS and that the depth of cell-cycle engagement stratifies neuronal fate and patient trajectories.
    Keywords:  ALS; cell cycle; motor neurons; neurodegeneration; patient heterogeneity
    DOI:  https://doi.org/10.1093/brain/awag391
  25. J Neurol. 2026 Nov 10. pii: 709. [Epub ahead of print]273(11):
       BACKGROUND AND OBJECTIVES: Emotion recognition deficits in amyotrophic lateral sclerosis (ALS) remain debated. We investigated whether patients with pure motor ALS (without cognitive and behavioural disturbances) and without clinically relevant mood disturbances are impaired in discriminating negative facial emotions, using a test without ceiling effects.
    METHODS: This cross-sectional study included 35 patients with pure motor ALS, based on the revised Strong criteria and operationalised using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS), without clinically relevant mood disturbances, alongside 35 age-, sex-, and education-matched cognitively and psychiatrically healthy controls. All participants completed a shortened five-emotion version of the Facial Emotion Intensity Rating Test - Congruent and Incongruent and the Facial Sex Matching Task (FSMT), a brief screening measure of non-emotional facial discrimination.
    RESULTS: Pure motor ALS patients showed poorer discrimination among negative facial emotions than healthy controls (p = 0.011, Cohen's d = 0.63). The group difference did not differ significantly across anger, fear, sadness, and disgust (p = 0.178). Similarly, the group difference in discrimination among negative emotions did not differ significantly from that in discrimination between negative emotions and happiness (p = 0.459). The two groups did not differ significantly on the FSMT.
    CONCLUSION: Discrimination of negative facial emotions was impaired in patients with pure motor ALS, suggesting that classification based on ECAS screening may underestimate social-cognitive involvement. Our findings are compatible with the concept of an ALS-frontotemporal spectrum disorder. Whether impaired emotion discrimination relates to additional cognitive or behavioural impairment remains to be determined. The clinical utility and reliability of our measure require further study.
    Keywords:  Amyotrophic lateral sclerosis; Facial emotion recognition; Frontotemporal dementia; Pure motor ALS; Social cognition
    DOI:  https://doi.org/10.1007/s00415-026-14241-x
  26. Cult Med Psychiatry. 2026 Nov 13. pii: 6. [Epub ahead of print]51(1):
      Medical students are commonly examined on ethically difficult clinical decisions, yet examination scripts have rarely been treated as a distinct empirical object in medical humanities. This article analyses 61 anonymised written examination responses from Danish medical students addressing acute respiratory failure in a fictional patient with advanced amyotrophic lateral sclerosis (ALS). The study is framed as a genre analysis of examination texts, operationalised through repeated close reading, inductive coding of recurrent textual moves, and abductive interpretation through Hartmut Rosa's concepts of acceleration and resonance. Four ethical repertoires were identified: accelerated stabilisation; prognostic triage and the limit of intervention; distributed responsibility and the search for a legitimate pause; and fragile resonance through attention to wishes, dignity, and palliative alternatives. Across the corpus, students wrote judgement through temporal distinctions between urgency and delay, reversibility and progression, and escalation and proportionate limitation. The findings do not show professionalism as such, but rather the institutionally legitimate ways in which professional judgement is made legible under assessment. Examination scripts matter for medical humanities because they make curricular normativity and evaluative pressure textually visible, showing how future clinicians are taught to write responsibility, uncertainty, and care into the same ethical scene. These repertoires also render an ableist prognostic imagination institutionally legible-one in which ventilator-dependent life is readily scripted in advance as a future to be avoided rather than supported-linking the temporal analysis to critical disability studies' account of the curative imaginary.
    Keywords:  Amyotrophic lateral sclerosis; Genre analysis; Medical education; Medical humanities; Temporality
    DOI:  https://doi.org/10.1007/s11013-026-10023-2
  27. Front Neurol. 2026 ;17 1949765
       Background: Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid-beta (Aβ) peptides within the cerebral vasculature and is a major cause of lobar intracerebral haemorrhage, cognitive impairment, and dementia. Vascular Aβ aggregates are enriched in shorter peptides (Aβ38 and Aβ40) whereas neuritic plaques, as observed in Alzheimer's disease pathology, predominantly contain longer Aβ peptides (Aβ42 and Aβ43). These pathological signatures are reflected by reduced cerebrospinal fluid (CSF) Aβ levels. However, the longitudinal dynamics of CSF Aβ peptides in CAA and their relationship with blood-brain barrier (BBB) dysfunction remain poorly understood.
    Methods: The MODEM-LAMBDA-C study is a longitudinal observational study including participants with CAA and age- and sex-matched control participants. At baseline, participants undergo clinical assessment, cognitive testing, blood pressure measurement, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the brain, blood sampling, and lumbar puncture to obtain CSF. At 2 years of follow-up, all assessments except MRI are repeated. Longitudinal changes in CSF Aβ peptide concentrations will be examined and related to cognitive performance, baseline MRI markers of cerebral small vessel disease and DCE-MRI-derived measures of BBB leakage. Additionally, CSF biomarkers of BBB dysfunction will be quantified and correlated with DCE-MRI markers of BBB dysfunction.
    Conclusion: By integrating biochemical and imaging markers of Aβ pathology and BBB dysfunction, the MODEM-LAMBDA-C study aims to provide a comprehensive understanding of disease mechanisms underlying CAA, potentially contributing to improved diagnosis and prognostic strategies.
    Clinical trial registration: https://onderzoekmetmensen.nl/en, identifier: NL85709.091.23.
    Keywords:  DCE-MRI; amyloid-beta; blood–brain barrier dysfunction; cerebral amyloid angiopathy; cerebrospinal fluid; longitudinal
    DOI:  https://doi.org/10.3389/fneur.2026.1949765
  28. BMJ Neurol Open. 2026 ;8(2): e001766
       Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited disease-modifying treatment options. Preclinical and clinical data suggest that cannabinoid-based therapies may exert neuroprotective and symptomatic benefits. We conducted a trial to evaluate the effects of cannabis-based medicine extract (CBME) on disease progression in patients with ALS.
    Methods: This was a randomised, double-blind, placebo-controlled trial. Participants received CBME or placebo for 6 months. The primary outcome was the difference in ALS Functional Rating Scale-Revised (ALSFRS-R) scores at the end of treatment (EOT). Secondary outcomes included adverse events, forced vital capacity (FVC), pain and spasticity measures, weight loss, cognition and quality of life.
    Results: Due to COVID-19 restrictions and driving limitations, only 17 participants were enrolled (CBME: n=8; placebo: n=9), and 8 completed treatment (4 per group). At EOT, adjusted mean ALSFRS-R scores were 31.67 for CBME and 34.33 for placebo (difference: -2.66; 95% CI -7.25 to 1.92; p=0.18; n=8). No significant differences were observed in secondary outcomes. Post hoc analyses suggested potential effects of CBME on pain and cognition for further confirmation: usual pain intensity decreased by 2.52 points (95% CI -8.92 to 3.87, p=0.34; n=8), a decrease of 3 days in the number of pain days (95% CI -28.90 to 22.59, p=0.75; n=8), executive function improved by 7.71 points (95% CI 0.90 to 14.52; p=0.04; n=8) and a 5.68-point improvement in memory (95% CI -0.29 to 11.64; p=0.06; n=8).
    Conclusion: This trial did not achieve the target sample size therefore was underpowered to demonstrate efficacy of cannabis in slowing ALS progression. However, exploratory analyses generated hypotheses regarding possible effects on pain and cognition which require confirmation in adequately powered studies.
    Trial registration number: (ID: NCT03690791) on 27 September 2018.
    Keywords:  ALS; CLINICAL NEUROLOGY; MOTOR NEURON DISEASE; NEUROMUSCULAR
    DOI:  https://doi.org/10.1136/bmjno-2026-001766
  29. Cell Rep. 2026 Nov 10. pii: S2211-1247(26)01362-8. [Epub ahead of print]45(11): 118283
      Selective autophagy receptors recognize and recruit harmful intracellular components to autophagosomes for degradation, and their dysfunction is linked to neurodegeneration, metabolic disorders, and cancer. Here, we identified TNFAIP3 interacting protein 1 (TNIP1) as an aggrephagy receptor implicated in neurodegenerative diseases. TNIP1 accumulated at polyubiquitinated protein aggregates upon proteotoxic stress. Genetic depletion of TNIP1 reduced protein aggregate clearance and increased axonal degeneration under proteotoxic stress. Mechanistically, TNIP1 enhanced protein aggregate clearance by assembling aggrephagy receptors, such as SQSTM1/p62 and TAX1BP1, onto protein aggregates. Gene expression analysis revealed that TNIP1 expression levels are reduced in patients with amyotrophic lateral sclerosis (ALS) with TAR DNA-binding protein 43 (TDP-43) inclusion pathology. Additionally, an ALS-associated TNIP1 mutant exhibited impaired association with TDP-43 aggregates and failed to rescue their autophagy-mediated degradation. These findings establish TNIP1 as an aggrephagy receptor and reveal its potential role as a therapeutic target for ALS and other proteinopathies.
    Keywords:  CP: cell biology; CP: neuroscience; TDP-43; TNIP1; aggrephagy; amyotrophic lateral sclerosis; autophagy receptor
    DOI:  https://doi.org/10.1016/j.celrep.2026.118283
  30. BMC Med Educ. 2026 Nov 11. pii: 1833. [Epub ahead of print]26(1):
       BACKGROUND: The evolution of Physiotherapy requires a shift from the biomedical model towards bioethical and humanistic approaches. This study explores how final-year students perceive their professional role when dealing with patients with complex neurodegenerative conditions, where traditional technical success is challenged by the irreversibility of the deterioration.
    METHODS: Qualitative research based on interpretative description. Thirty final-year students from the University of Almería (Spain) took part, divided into five working groups. Three training sessions and discussions were held on Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, stroke and Rett syndrome. The data were analysed using thematic analysis and triangulation by researchers external to the study, with reflexivity ensured through logbooks.
    RESULTS: A shift in clinical reasoning was identified, with sensitivity taking precedence over technique. Students redefined therapeutic success in terms of "comfort" and support, valuing "microscopic achievements" such as the preservation of dignity and the alleviation of distress. Of particular note is the ability to adapt ethical principles according to the patient's cognitive integrity (autonomy in ALS versus protection in Alzheimer's) and the integration of the carer as an inseparable part of the therapeutic process.
    CONCLUSION: Future physiotherapists perceive humanization and the empathetic interpretation of non-verbal cues as essential therapeutic tools. Unlike previous studies focused on clinical experience, this research explores pre-clinical ethical maturation, offering a unique perspective on the educational foundation and humanistic predisposition of future graduates prior to their immersion in the healthcare system. It is imperative that academic curricula formally integrate competencies in bioethics, palliative care and emotional management to prepare graduates for extreme vulnerability and prevent early professional burnout.
    Keywords:  Bioethics; Humanization of care; Medical education; Neurodegenerative diseases; Physiotherapy
    DOI:  https://doi.org/10.1186/s12909-026-10077-1
  31. Diagnostics (Basel). 2026 Oct 29. pii: 3573. [Epub ahead of print]16(21):
      Background: Electromyogram (EMG) is considered for the diagnosis of amyotrophic lateral sclerosis (ALS). We investigated how frequently an initial electrophysiological evaluation is performed in ALS patients. Objective: We aimed to identify ALS cases using the feature selection algorithm (FSA). A pattern of feature involvement was expected in the early phase of ALS based on the typical consistent involvement of a few particular muscles in the late stages. Methods: We used a clinical and EMG dataset of 36 patients (21 ALS patients and 15 healthy) for analysis. The present approach used a Random Forest (RF)-based machine learning (ML) algorithm for the prediction of ALS patients. The goal of this study was to determine how feature selection techniques can enhance machine learning algorithms that can be used in real-time applications. Findings: The experimental findings demonstrate the superior performance of the proposed model. This work demonstrates how machine learning models can offer important predictive insights in ALS, improving knowledge of disease dynamics and aiding patient care. According to the comparison results, the RF model utilizing the feature selection algorithm demonstrated a positive improvement, and the accuracy of the RF model with and without the feature selection technique was found to be 87.50% and 75%, respectively. Conclusions: The algorithm improved the model accuracy from 75% to 87.50%, resulting in an absolute increase of 12.5 percentage points in classification accuracy. This study found that fibrillation, positive sharp waves (PSW), and fasciculation features were high-yielding in EMG of ALS cases.
    Keywords:  amyotrophic lateral sclerosis (ALS); electromyography (EMG); machine learning (ML); motor neuron disease (MND); muscles
    DOI:  https://doi.org/10.3390/diagnostics16213573
  32. J Med Internet Res. 2026 Nov 12. 28 e106677
       Unlabelled: Amyotrophic lateral sclerosis (ALS) clinical trials need outcome measures that complement established end points while capturing how people function in daily life. In this viewpoint, we draw on our collective experience in ALS research, clinical trials, digital-measure development, and regulatory science, together with published evidence, a preliminary patient survey, stakeholder discussions, and experience from multisite actigraphy studies. We argue that the field now has a substantial base of longitudinal data and candidate measures, but lacks the coordinated framework needed to compare, prioritize, and validate them across studies. We identify 4 linked priorities: adopt fit-for-purpose measures in stages and within defined contexts of use; harmonize data collection and analysis; use data to shortlist and validate measures across cohorts; and prepare actigraphy methods for trial adoption through early industry and regulatory engagement. Across these priorities, actigraphy should complement rather than replace established clinical outcomes, with its integration guided by patient relevance, ALS phenotypic heterogeneity, participant, and caregiver burden, and the intended context of use. Our central message is that progress now depends less on generating additional isolated datasets or measures than on coordinating the evaluation of existing assets, and aligning future evidence generation.
    Keywords:  accelerometry; actigraphy; amyotrophic lateral sclerosis; clinical trial design; digital clinical outcome assessments; patient-centered outcomes; regulatory pathways
    DOI:  https://doi.org/10.2196/106677
  33. bioRxiv. 2026 Oct 12. pii: 2026.10.09.756561. [Epub ahead of print]
      TAR DNA-binding protein 43 (TDP-43) is an RNA-binding protein whose low-complexity domain (LCD) mediates self-assembly, liquid-liquid phase separation, and pathological aggregation associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Previous studies have established the central ultraconserved region (UCR) of the LCD as a major determinant of TDP-43 self-association. However, the contribution of the evolutionarily conserved C-terminal region remains poorly understood. To identify LCD residues required for self-assembly, we systematically analyzed 47 ALS-associated substitutions distributed throughout the TDP-43 LCD using hydrogel-binding and thioflavin T (ThT) assays. Several ALS-associated substitutions within the C-terminal conserved region (CCR) markedly reduced hydrogel incorporation and impaired fibrillization. Similar assembly defects were observed for methionine-to-serine substitutions at two conserved CCR residues, M405 and M414. Furthermore, CCR-containing C-terminal fragments encompassing residues 360-414 or 379-414 formed ThT-positive fibrillar assemblies in vitro . The assembly kinetics exhibited a characteristic lag phase followed by rapid fluorescence growth, consistent with the formation of cross-β-rich assemblies. These findings identify the CCR as an additional conserved self-assembly module within the TDP-43 LCD and expand the prevailing UCR-centered model of TDP-43 assembly. The observation that multiple ALS-associated substitutions reduce rather than enhance self-association further raises the possibility that disruption of normal TDP-43 assembly contributes to disease pathogenesis.
    DOI:  https://doi.org/10.64898/2026.10.09.756561
  34. Diagnostics (Basel). 2026 Oct 28. pii: 3539. [Epub ahead of print]16(21):
      Background/Objectives: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system, and magnetic resonance imaging (MRI) plays a central role in its diagnosis and monitoring. Because different MRI sequences provide complementary information about MS-related pathology, jointly exploiting multiple sequences may improve automated classification. However, many existing automated MS classification studies rely on limited sequence information, are not consistently evaluated under subject-independent protocols, and are constrained by the scarcity of publicly available multi-sequence datasets organized at the subject level. Methods: To address these gaps, we collected and publicly released a new multi-sequence brain MRI dataset and proposed DenseGated-MSNet, a novel end-to-end multi-input deep learning model for MS versus non-MS classification. DenseGated-MSNet processes each co-acquired MRI sequence in parallel through an independent sequence-specific DenseNet-121 branch and integrates the resulting representations through a proposed input-dependent gated feature-level fusion mechanism. Under a strict subject-independent evaluation protocol, the model configuration was determined on a subject-independent development set, and the performance of the final model was internally evaluated using five-fold subject-independent cross-validation on the same cohort at the image and subject levels. Results: In internal five-fold subject-independent cross-validation, DenseGated-MSNet achieved a pooled subject-level accuracy of 90.57% (95% CI: 86.44-93.53%) and an AUC of 0.947 (95% CI: 0.918-0.976). The learned gate values also provided sequence-level modulation information, indicating how strongly each MRI sequence was weighted during multi-sequence integration. Conclusions: Overall, these findings suggest that DenseGated-MSNet can effectively integrate complementary information from multiple MRI sequences for discriminating established MS from selected non-MS controls, while providing sequence-level modulation information. Together with the released dataset, the proposed framework provides a reproducible basis for future subject-independent MS classification studies.
    Keywords:  deep learning; gated feature-level fusion; multi-input classification; multi-sequence brain MRI; multiple sclerosis
    DOI:  https://doi.org/10.3390/diagnostics16213539
  35. Front Med (Lausanne). 2026 ;13 1812134
      Multiple Sclerosis (MS) is an immune-mediated central nervous system condition with heterogeneous clinical manifestations, progressive neurodegeneration, and considerable variability in disease trajectory. Recent advances in artificial intelligence (AI), particularly machine learning (ML) methods, have improved MS diagnosis and risk prediction. However, comprehensive review studies emphasizing the potential of existing AI-powered MS diagnosis remain limited. Thus, this study investigates the utilization of multimodal data by AI models to enhance diagnostic accuracy, evaluate disease progression, and optimize personalized care strategies. By adhering to PRISMA guidelines, this review included 26 studies encompassing MRI-based analysis, retinal OCT imaging, blood transcriptomics, SNP genotyping, and multimodal clinical datasets. An additional classification of these studies by modality was performed, and they were assessed with respect to dataset size, performance metrics, biomarkers, methodological robustness, and model interpretability. The findings indicate a consistent trend toward outstanding diagnostic performance, with some AI models achieving accuracies exceeding 95% using medical imaging and genomic data. However, limited external validation and interpretability procedures create a gap in clinical applicability and trustworthiness. This review highlights AI's growing potential to revolutionize MS diagnosis.
    Keywords:  artificial intelligence; deep learning; feature representation; gene expression; machine learning; medical imaging; multiple sclerosis diagnosis
    DOI:  https://doi.org/10.3389/fmed.2026.1812134
  36. ACS Nano. 2026 Nov 10. 20(44): 29534-29549
      For pharmacological treatments of brain disorders, the blood-brain barrier (BBB) poses a formidable obstacle, tightly restricting the cerebral uptake of therapeutic agents. Tight junction (TJ) binders, including peptides, proteins, and monoclonal antibodies, that specifically bind to the extracellular domains (ECDs) of TJ proteins are increasingly being explored as BBB-weakening agents for enhanced drug delivery to the brain. Given that nanobodies (Nbs) can access epitopes that are often inaccessible to conventional antibodies, we obtained 16 Nbs with unique CDRs via immunization of alpaca with the ECD of either human (h) or murine JAM-1 (mJAM-1), a major TJ protein. Twelve Nb candidates exhibited high-affinity binding to mJAM-1, as measured by surface plasmon resonance (SPR), and these interactions were further validated for 9 Nbs by immunostaining of JAM-1-overexpressing cells. Five Nbs were found to weaken the barrier of the eGFP-hCldn5-MDCKII cellular monolayer, as shown by reduced transendothelial electrical resistance (TEER). X-ray crystallography revealed that the lead barrier-weakening Nb, E6, binds to the membrane-proximal nondimeric D2 domain of mJAM-1. Mutating key residues at this interface eliminated the BBB-weakening effect of E6, as evidenced by unaltered sodium fluorescence (NaFI) leakage in both eGFP-hCldn5-MDCKII and mJAM1-mGL-MDCKII cellular monolayers compared with the nontreated control. Our study highlights the potential of JAM-1-targeting Nbs as BBB modulators, offering a promising approach for generating TJ binders to enhance brain drug delivery.
    Keywords:  Blood–brain barrier; JAM-1; X-ray crystallography; nanobody; tight junction binder
    DOI:  https://doi.org/10.1021/acsnano.6c07541
  37. Exp Biol Med (Maywood). 2026 ;251 11350
      SEL1L (suppressor/enhancer of lin-12-like) is an endoplasmic reticulum (ER) transmembrane protein that serves as a key regulatory molecule in the endoplasmic reticulum-associated degradation (ERAD) pathway, playing a central role in maintaining intracellular protein homeostasis. This paper provides a systematic review of SEL1L's structural characteristics, the molecular mechanisms by which it forms a functional complex with the E3 ubiquitin ligase HMG-CoA reductase degradation protein 1 (HRD1, encoded by SYVN1) to synergistically execute ERAD, and its pathophysiological significance in the onset and progression of various diseases. Research indicates that SEL1L dysfunction is closely associated with pathogenic protein aggregation in neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis), protein homeostasis imbalances during tumorigenesis, cellular metabolic dysregulation in metabolic disorders (e.g., diabetes, lipid metabolism disorders), and immune system dysfunction. Furthermore, the expression levels or variants of SEL1L exhibit specific alterations across different tumor tissues, suggesting its potential as a disease biomarker and therapeutic target. This paper aims to synthesize existing research, elucidate the 'gatekeeper' role of SEL1L in multiple physiological and pathological processes, and explore the prospects for developing novel therapeutic strategies by targeting the SEL1L-HRD1 complex and related pathways.
    Keywords:  AD; PD; SEL1L; immunity; metabolic diseases; neurodegenerative diseases; tumor
    DOI:  https://doi.org/10.3389/ebm.2026.11350
  38. Nature. 2026 Nov 11.
      TDP-43 nuclear depletion is a defining pathological feature of amyotrophic lateral sclerosis and frontotemporal dementia that induces widespread cryptic splicing defects in hundreds of transcripts1-8. Despite this, whether TDP-43 loss affects synaptic function has remained unclear. Here we show that TDP-43 loss induces a predegenerative state in which neurons remain structurally intact but suffer a substantial breakdown in synaptic communication. Genetic correction of a single cryptic splicing event in UNC13A was sufficient to rescue these deficits. We developed splice-switching antisense oligonucleotides that correct UNC13A cryptic splicing in human cortical and spinal motor neurons and in a humanized mouse model. In human neurons this intervention restored spontaneous and evoked synaptic vesicle release, release probability at individual synapses and wider network synchrony. Together, this establishes UNC13A splice correction as a mechanistically defined and genetically validated therapeutic strategy relevant to roughly 97% of patients with amyotrophic lateral sclerosis and roughly 50% of patients with frontotemporal dementia with TDP-43 pathology.
    DOI:  https://doi.org/10.1038/s41586-026-11256-2
  39. Phytother Res. 2026 Nov 11.
      The multifactorial complexity of neurodegenerative diseases (NDs), including Alzheimer's and Parkinson's disease, limits the efficacy of single-target therapies. Natural glycosides exhibit promising neuroprotective potential, but their clinical translation is hindered by poor oral bioavailability and limited blood-brain barrier (BBB) penetration. The gut-brain axis offers a framework for understanding their potential biological effects beyond direct central exposure. This review explores the multi-target mechanisms of natural glycosides in NDs, focusing on their interactions with the gut-brain axis. A narrative literature search was conducted in PubMed, Web of Science, and ScienceDirect for studies published up to June 2026. Relevant literature on glycosides, NDs, gut microbiota, microbial biotransformation, pharmacokinetics, and neuroprotective mechanisms was critically reviewed. Natural glycosides may affect ND-related processes through gut-mediated and systemic/central mechanisms. Poorly absorbed glycosides can interact with intestinal microbiota, potentially modulating microbial composition, intestinal barrier integrity, and short-chain fatty acids (SCFAs) production. Microbial biotransformation may generate metabolites with altered physicochemical properties and systemic exposure, potentially enhancing central nervous system accessibility in a compound-specific manner. Experimental evidence also suggests effects on neuroinflammation, mitochondrial homeostasis, autophagy, and synaptic function. However, most findings remain preclinical, with limited direct human evidence. The gut-brain axis provides a valuable perspective for understanding the biological activities of natural glycosides despite their limited oral bioavailability and BBB penetration. Further pharmacokinetic studies, causal investigations of microbiota-mediated effects, and controlled clinical trials are needed to establish their therapeutic potential in NDs.
    Keywords:  Alzheimer's disease; Parkinson's disease; glycosides; gut–brain axis; neurodegenerative diseases
    DOI:  https://doi.org/10.1002/ptr.70521
  40. Int J Pharm X. 2026 Dec;12 100693
      Brain diseases remain a significant challenge in the field of modern medicine. The protective function of the blood-brain barrier (BBB) also complicates drug delivery for neurological disorders. However, under certain pathological conditions, the BBB is compromised during the progression of these pathophysiological processes. To integrate with clinical treatments, precise and personalized requirements exist for basic research. Three-dimensional (3D) in vitro systems, particularly organoids, serve as valuable models for preclinical disease research. Starting from the functionality and feasibility of organoids, this review explores their potential roles and applications in brain diseases. It also discusses advanced technologies to overcome in vitro modeling challenges and their applications in evaluating therapeutic strategies and drug delivery. Moreover, with the ability to predict and rapidly screen effective drugs, organoid modeling will be valuable in accelerating the clinical translation of new therapeutics.
    Keywords:  Application; BBB; Brain disease; Drug delivery; Organoids
    DOI:  https://doi.org/10.1016/j.ijpx.2026.100693
  41. BMC Med Imaging. 2026 08 13. pii: 604. [Epub ahead of print]26(1):
       PURPOSE: The precise diagnosis of Parkinson's Disease (PD) continues to pose a considerable barrier in clinical neurology. This work investigates the capability of sophisticated deep learning architectures to improve Parkinson's disease identification via Magnetic Resonance Imaging (MRI) scans, aiming to improve diagnostic sensitivity and specificity.
    METHOD: This research implements an automated PD classification framework utilizing deep learning models to analyze real-time MRI scans. CNN models and Transformers that leverages the inherent spatial information within MRI scans for automated feature extraction and classification of PD was implemented. The comparative analysis of diverse architectures aimed to discern the optimal feature extraction and classification strategies for distinguishing PD-affected brains from healthy controls was performed. K-fold cross-validation was conducted to evaluate the reliability of dataset partitioning and to ensure model generalizability.
    RESULTS: The QNN demonstrated superior performance during training and validation with accuracy of 0.9851 and 0.9731 respectively. Among the Transformer-based architectures, the Swin Transformer achieved a training and validation accuracy of 0.9712 & 0.9673. In the category of CNN-based models, ResNet50 exhibited the highest accuracy, attaining 0.9322 during training and 0.9192 during validation. The K-fold cross-validation results corroborated the stability and consistency of the model performances with the 80:20 data split, reinforcing the robustness of the proposed approach. Furthermore, to assess the generalizability of the best-performing model, an external validation was conducted using the Parkinson's Progression Markers Initiative (PPMI) dataset. The results demonstrated comparable performance trends, thereby confirming the adaptability of the DL model to independent datasets.
    CONCLUSION: This study's findings highlight the capability of deep learning-driven neuroimaging analysis in facilitating automated and precise PD diagnosis. This investigation provides a scalable and clinically viable AI framework that enhances diagnostic accuracy, thereby supporting clinicians in disease detection and improving patient management strategies.
    Keywords:  CNN; MRI image classification; Parkinson’s disease; QNN; Swin transformer; Vision transformer
    DOI:  https://doi.org/10.1186/s12880-026-02639-y
  42. Nat Commun. 2026 10 15. pii: 11662. [Epub ahead of print]17(1):
      Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron (MN) loss caused by early axonal and synaptic changes. However, the mechanisms underlying these changes remain incompletely understood. Here, we exploit FUS-ALS to interrogate cell compartment-specific changes in RNA expression and regulation in human induced pluripotent stem cell (iPSC)-derived MN. This approach identifies compartment-specific 3' untranslated region (3'UTR) isoform expression in human healthy control MN axons. Further, it unveils altered 3' UTR isoforms in ALS in different cellular compartments in genes such as SNCA, previously linked to neurodegeneration. Expression of SLITRK2 is most strongly and consistently upregulated across multiple FUS-ALS models, and its knockdown normalizes axonal defects linked to FUS-ALS. Using a fully iPSC-derived neuromuscular microfluidics protocol, we show that SLITRK2 knockdown in FUS-ALS MN rescues neuromuscular junction (NMJ) signaling without affecting NMJ innervation or MN hypo-excitability. Our study provides insight into compartment-specific 3'UTR expression in ALS, presents a robust iNMJ-on-a-chip model, and links elevated SLITRK2 to axonal and synaptic defects in FUS-ALS.
    DOI:  https://doi.org/10.1038/s41467-026-78419-7
  43. Adv Pharm Bull. 2026 Jun;16(2): 252-267
      Treatment for Parkinson's disease (PD) faces two significant challenges: first, the blood-brain barrier (BBB) and second, a therapeutic strategy that alleviates symptoms instead of stopping the disease progression. The BBB prevents over 98% of small-molecule drugs, leaving neuroprotective options mostly inaccessible. Nanotechnology is being developed to overcome existing limitations, paving the way for more precise and effective delivery to the brain. This review goes beyond listing types of nanocarriers to critically synthesise our understanding of nanoparticle (NP)-based strategies for PD, evaluating their therapeutic potential in relation to the challenges of real-world application. Evidence from various systems is evaluated, from lipid-based carriers and polymeric NPs to advanced constructs such as dendrimers, to see how these might enhance brain bioavailability, support sustained release, and directly target disease processes, including alpha-synuclein aggregation and neuroinflammation. The paper thoroughly examines the primary barriers to clinical application, including biocompatibility concerns, scalability of manufacturing, and an evolving regulatory landscape. Looking ahead, PD nanomedicine will focus on designing theranostic platforms with multiple functions. That future will depend upon close collaborations across disciplines to turn compelling preclinical results into practical, disease-modifying therapies.
    Keywords:  Drug delivery; Nanoparticles; Nanotechnology; Parkinson’s disease; Targeted therapy
    DOI:  https://doi.org/10.34172/apb.46162
  44. Front Neurol. 2026 ;17 1917665
       Purpose: To describe a new radiological finding-an asymmetric deposition of paramagnetic substances in the ipsilateral basal ganglia to a mainly frontal supratentorial lesion-retrospectively observed via Magnetic Resonance (MR), using a Susceptibility Weighted Imaging sequence (SWI), and develop a reliable hypothesis of its possible origin in the context of a transsynaptic degeneration.
    Methods: Following initial clinical observations of this specific MR sign, a systematic retrospective database review of the more recent reports of any case with a history of tumors or other frontal pathology was conducted, to evaluate using the SWI sequence if this asymmetric deposition of paramagnetic substances in the basal ganglia was consistently present. In addition, the identified cases (frontal pathology with asymmetric deposition of paramagnetic substances in the basal ganglia) showed signs of a pathology different from the one mentioned above, or in other areas of the brain, that could justify the presence of these deposits.
    Results: Within the retrospectively evaluated cohort of 35 patients, the primary supratentorial etiologies were diverse, from tumors, ischemic pathology or previous surgery, and the predominant location was the frontal lobes. Different symptoms were present in 54.3% of the patients. According to the qualitative analysis carried out using the SWI sequences, this deposition tended to occur predominantly in the globus pallidus and substantia nigra ipsilateral to a supratentorial lesion. Furthermore, 11 out of the 35 cases (32%) had incipient anterograde degeneration of the ipsilateral corticospinal pathway. It should also be noted in post-surgical patients that this asymmetric deposition of paramagnetic substances did not exist in the studies prior to the intervention.
    Conclusion: It is hypothesized that this structural asymmetry represents an early sign in MR in the context of transsynaptic degeneration with associated iron deposition in the basal ganglia. This hitherto undescribed finding could be important to further knowledge of the pathophysiology of basal ganglia, and could serve as a biomarker and prognostic factor in patients with frontal cortex pathology.
    Keywords:  basal ganglia; iron deposition; magnetic resonance; susceptibility weighted imaging sequence; transynaptic degeneration
    DOI:  https://doi.org/10.3389/fneur.2026.1917665
  45. Int J Mol Sci. 2026 Oct 25. pii: 9529. [Epub ahead of print]27(21):
      Skeletal muscle undergoes structural and functional decline due to aging and neuromuscular disorders such as amyotrophic lateral sclerosis (ALS), both of which impact protein expression and contribute to muscle atrophy. This study investigates how aging and the SOD1G93A ALS-related mutation affect the expression of eight genes previously linked to sarcopenia (PF4, OIT3, MMRN1, MASP1, C1R, SVEP1, VCAN and SPTB) but not yet characterized in muscle tissue. To this end, we analyzed their expression (1) during muscle aging in WT mice (5 and 24 months), (2) in SOD1G93A-transfected myotube cells in vitro, (3) in a muscle-specific SOD1G93A mouse model (5 and 24 months), and (4) in a systemic SOD1G93A transgenic mouse at different disease stages (60 and 120 days) by quantitative PCR. All eight target genes were expressed in skeletal muscle and most of them showed increased transcription with aging. In ALS models, gene expression was significantly overexpressed at early stages, particularly in muscle-specific (MLC/SOD1G93A) and systemic (SOD1G93A) models, mimicking aging-related profiles. These alterations attenuated with disease progression, suggesting an early transient muscle response to ALS-linked SOD1 mutations. Hence, this study demonstrates that sarcopenia-associated proteins are actively expressed and modulated in skeletal muscle during aging and ALS and suggests convergent response mechanisms.
    Keywords:  ALS; aging; atrophy; sarcopenia; skeletal muscle
    DOI:  https://doi.org/10.3390/ijms27219529
  46. Neuroimaging Clin N Am. 2027 Feb;pii: S1052-5149(26)00072-9. [Epub ahead of print]37(1): 89-101
      Limbic-predominant age-related TAR DNA-binding protein 43 encephalopathy, hippocampal sclerosis-aging, primary age-related tauopathy, argyrophilic grain disease, and frontotemporal lobar degeneration fused in sarcoma are increasingly recognized neurodegenerative disorders that frequently mimic Alzheimer's disease (AD) and commonly coexist with AD pathology in older adults. As disease-modifying therapies emerge, accurate identification of these non-AD and mixed pathologies has become clinically important. This article reviews current clinicopathologic concepts and highlights the role of MR imaging and molecular PET imaging in differentiating limbic-predominant and frontotemporal neurodegeneration, estimating concurrent AD pathology, and interpreting complex multietiology dementia patterns.
    Keywords:  AGD; Alzheimer’s disease; Copathology; FTLD-FUS; LATE; MRI; PART; PET
    DOI:  https://doi.org/10.1016/j.nic.2026.07.005
  47. J Lipid Res. 2026 Nov 13. pii: S0022-2275(26)00217-8. [Epub ahead of print] 101187
      Sphingolipid homeostasis is critical for structural and functional integrity of neurons in the central and peripheral nervous systems. Serine-palmitoyltransferase (SPT) is the first and the rate-limiting metabolic entry point into the de novo sphingolipid biosynthesis. Mutations in SPT subunits, SPTLC1 and SPTLC2 lead to contrasting patient phenotypes, including amyotrophic lateral sclerosis (ALS) and hereditary sensory and autonomic neuropathy type 1 (HSAN1). A third mixed sensory-motor phenotype is attributed to distinct mutation sets in SPTLC1 and SPTLC2. However, a direct comparison of the metabolic consequences of mutations spanning these disease conditions has not been performed. Here, we demonstrate that SPTLC1- and SPTLC2-ALS variants contribute to enhanced sphingolipid synthesis as the ceramide-mediated homeostatic control is impaired. In contrast, HSAN1 variants display altered substrate selectivity, favoring non-canonical 1-deoxysphingolipid production while retaining canonical feedback regulation. Mixed sensory-motor mutants exhibit a third metabolic state, with elevated 1-deoxysphingolipid formation and, in contrast to HSAN1 variants, decreased feedback inhibition and increased canonical sphingolipid synthesis. Sphingolipid profiling reveals that ALS variants are characterized by preferential accumulation of dihydrosphingolipids and sphingolipid species containing C18-C22 N-acyl chains, whereas very-long-chain (C22-C26) 1-deoxysphingolipids predominate in HSAN1. The SPT-variants associated with mixed sensory-motor symptoms show elevated levels of both lipid types. Notably, the metabolic distinction is disease-specific and SPT subunit independent. The data support the view that segregated shifts in sphingolipid flux underlie divergence of clinical phenotypes in SPT-variants. These metabolic configurations generate testable predictions for therapy: L-serine supplementation may benefit HSAN1 but could prove counterproductive in ALS and sensory-motor disease conditions.
    Keywords:  1-deoxysphingolipids; Serine-palmitoyltransferase (SPT); amyotrophic lateral sclerosis (ALS); hereditary sensory and autonomic neuropathy type 1 (HSAN1); sensory-motor neuropathy; sphingolipid metabolism
    DOI:  https://doi.org/10.1016/j.jlr.2026.101187
  48. Curr Med Imaging. 2026 Nov 03.
       INTRODUCTION/OBJECTIVE: Artificial Intelligence (AI), including machine learning and deep learning, is increasingly applied to brain Magnetic Resonance Imaging (MRI) for disease detection, classification, segmentation, and clinically relevant prediction. This review aimed to map the evidence on AI-assisted brain MRI diagnosis, identify methodological and clinical translation gaps, and propose priorities for future research.
    METHODS: This scoping review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. PubMed/MEDLINE, Scopus, IEEE Xplore, and Web of Science were searched for peer-reviewed English-language publications from January 2018 to April 2026. Data were charted according to disease domain, study design, AI method, dataset, validation strategy, performance metrics, explainability, and key limitations.
    RESULTS: The search identified 1,020 records. After duplicate removal and screening, 61 publications were included, comprising 24 original studies used for the primary evidence map and 37 reviews or commentaries used for contextual synthesis. Evidence was strongest for brain tumor imaging and Alzheimer's disease, whereas stroke, multiple sclerosis, pediatric neuroimaging, and rare neurological conditions were underrepresented. Most studies relied on public benchmark datasets and retrospective validation, whereas external validation, prospective clinical evaluation, subgroup analysis, explainability, and workflow integration were inconsistently reported.
    DISCUSSION: The findings indicate that AI-assisted brain MRI research remains unevenly developed and is constrained by dataset dependence, limited external validation, limited prospective clinical evaluation, and inconsistent reporting of explainability, subgroup performance, and workflow integration.
    CONCLUSION: AI shows promising research-stage potential for brain MRI-based diagnosis, particularly in brain tumor analysis and Alzheimer's disease classification. Future research should prioritize multicenter validation, diverse and disease-specific datasets, explainable and equitable AI design, transparent reporting, and prospective evaluation within real clinical workflows.
    Keywords:  Alzheimer’s disease; Artificial intelligence; Brain MRI; Brain tumor; Clinical translation; Deep learning; Machine learning; Neuroimaging
    DOI:  https://doi.org/10.2174/0115734056523075261026051524
  49. Dentomaxillofac Radiol. 2026 Nov 12. pii: twag076. [Epub ahead of print]
       OBJECTIVES: To estimate standalone artificial intelligence (AI) diagnostic performance in temporomandibular joint (TMJ) imaging across input modality-target pairings.
    METHODS: Four databases were searched through 18 June 2026. Eligible studies assessed standalone imaging AI and supplied an exact test-set 2 × 2 table in the report or after author contact. Four pairings were analysed by bivariate meta-regression. Two reviewers applied QUADAS-3 at estimate level.
    RESULTS: Sixteen studies contributed 17 estimates. For disc displacement, magnetic resonance imaging input yielded pooled sensitivity 0.924 (95% CI, 0.859-0.960) and specificity 0.812 (0.709-0.885), compared with 0.765 (0.618-0.867) and 0.741 (0.592-0.850) for panoramic or cone-beam computed tomography input. The sensitivity difference was 0.159 and remained 0.152-0.198 in leave-one-out and replicate analyses; the omnibus pairing test was not significant (χ²(6) = 10.38, P = .110). Reference-standard relation and pairing partitioned the disc-displacement evidence identically. No estimate had low overall risk of bias, and several otherwise eligible estimates lacked exact published 2 × 2 data.
    CONCLUSIONS: Sensitivity was higher when disc displacement was depicted directly on magnetic resonance imaging than when inferred from imaging that does not depict the disc. However, the cross-domain group contained only three estimates, the omnibus pairing test was not significant, and design factors were entangled. Performance should therefore be interpreted by pairing, while direct depiction versus proxy inference requires prospective testing.
    ADVANCES IN KNOWLEDGE: TMJ imaging AI performance should be interpreted in the context of the input modality-target pairing rather than as a property of the algorithm alone; exact test-set confusion matrices are essential for verification.
    Keywords:  Artificial intelligence; Degenerative joint disease; Disc displacement; Machine learning; Temporomandibular joint
    DOI:  https://doi.org/10.1093/dmfr/twag076
  50. Front Immunol. 2026 ;17 2002570
      Neurons, glial cells, and immune cells engage in extensive bidirectional communication within the central nervous system (CNS) through shared receptors, ligands, and secreted mediators. Glial cells - particularly astrocytes and microglia - serve not merely as structural support but as central immunomodulatory hubs that relay neural signals to immune effectors. In the context of CNS malignancies, glioblastoma (GBM) co-opts these neuroimmune networks to establish an immunosuppressive tumor microenvironment. This narrative review is organized around five interconnected axes. After summarizing the receptor and ligand repertoires of CNS-resident cell types, we examine (i) the neural inputs that reach glioblastoma and the reciprocal signals the tumor returns to the neural compartment; (ii) the remodeling of glial cells and glioma-associated macrophages/microglia; (iii) the innate and adaptive immune suppression that follows, including a "chemical-cellular" suppressive architecture; (iv) the blood-brain barrier and neurovascular interface that constrain immune access; and (v) the therapeutic opportunities arising from each of these layers.
    Keywords:  glial cells; glioma; glioma-associated macrophages/microglia; immune cells; nervous system
    DOI:  https://doi.org/10.3389/fimmu.2026.2002570
  51. Nutrients. 2026 Oct 25. pii: 3512. [Epub ahead of print]18(21):
      Due to increasing prevalence and burden of the central nervous system (CNS) disorders and challenges associated with their treatment, there is ongoing search for new therapeutic targets, frequently conducted in the area of natural products. Tea (derived from Camellia sinensis) contains a wide range of bioactive compounds (polyphenols, alkaloids and amino acids) which positively affect general health and function of many systems, including CNS. The aim of this narrative review was to present up-to-date evidence of beneficial effects of tea and its compounds on CNS functions and to outline the most promising perspectives for their utility in management of neurological conditions. Based on extensive literature search, the authors demonstrate biochemical properties of tea-derived substances, molecular mechanisms of their antioxidative, anti-inflammatory and cytoprotective activity, as well as pathways of their specific impact on CNS. The evidence is presented from experimental and clinical studies investigating effects of tea and its compounds on the prevention or amelioration of neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, Huntington's disease), multiple sclerosis, cerebrovascular disease and brain tumors. Finally, limitations and barriers to these investigations are discussed and their emerging future directions are suggested.
    Keywords:  central nervous system disorders; polyphenols; prevention; tea; treatment
    DOI:  https://doi.org/10.3390/nu18213512
  52. J Clin Med. 2026 Nov 01. pii: 8491. [Epub ahead of print]15(21):
      Background/Objectives: Multiple sclerosis (MS) is a central nervous system disease that can cause severe disability. Identifying biomarkers associated with disease progression and disability is important for MS follow-up. Optical coherence tomography (OCT) parameters, measurements of cervical spinal atrophy, and cognitive and motor performance tests were evaluated along with their changes over one year to investigate their potential role in MS follow-up. Methods: This retrospective study included 79 patients with MS. OCT and cervical magnetic resonance imaging performed at 1-year intervals, along with cognitive and motor performance tests, were evaluated. Cervical mean cross-sectional area (mCSA) was used to assess spinal atrophy. Results: Over one year, cervical mCSA and ganglion cell-inner plexiform layer (GCIPL) measurements significantly decreased. Their annual changes were not significantly correlated in the Pearson analysis. The age-, sex-, and disease-duration-adjusted linear analysis likewise did not identify a statistically significant association. Conclusions: Cervical mCSA and GCIPL thickness significantly decreased over one year, but their changes were not significantly correlated. These findings suggest that cervical mCSA and GCIPL may provide complementary information on longitudinal structural changes in MS. However, because measurement reproducibility and absolute error were not quantified for the single-reader cervical measurements, the observed mCSA decrease should be interpreted cautiously, as the extent to which it reflects biological change rather than measurement variability remains uncertain. The clinical relevance of these findings requires further validation.
    Keywords:  multiple sclerosis; optical coherence; spinal cord; tomography
    DOI:  https://doi.org/10.3390/jcm15218491
  53. PeerJ. 2026 ;14 e21710
       Background: Public awareness of amyotrophic lateral sclerosis (ALS) is limited worldwide, with potential implications for timely recognition, care seeking, and social support. Data from the Northern Border Region of Saudi Arabia are lacking. This study aims to assess community awareness and knowledge of ALS and identify predictors of good awareness among adults in the Northern Border Region of Saudi Arabia.
    Methods: A cross-sectional survey of 1,277 adults used a structured self-administered questionnaire covering sociodemographic characteristics, general awareness, knowledge, attitudes, personal experience, and information sources. Awareness was scored from 16 knowledge items and categorized as good (≥ 60%) or poor (<60%). Descriptive statistics, chi-square tests with Cramér's V, and multivariable logistic regression were applied; model performance was assessed using the Hosmer-Lemeshow test and area under the receiver operating characteristic (ROC) curve (AUC).
    Results: Participants were mainly young to middle-aged, female, and university-educated, and most worked outside the health field. Although 45.2% had heard of ALS, 90.8% showed poor awareness, while only 9.2% showed good awareness. Uncertainty predominated regarding prognosis, risk groups, neuroanatomical involvement, non-motor symptoms, curability, and diagnostic difficulty. Age and occupation were associated with awareness in bivariate analyses but lost significance after adjustment. Never having heard of ALS markedly reduced the odds of good awareness (adjusted odds ratio (AOR) = 0.167, 95% confidence interval (CI) [0.097-0.288], p < 0.001), while using the internet and healthcare sources was associated with higher awareness. The model showed good calibration (Hosmer-Lemeshow p = 0.891) and discrimination (AUC = 0.820).
    Conclusions: Community awareness and knowledge of ALS in this region are poor, underscoring the need for targeted digital and healthcare-based educational initiatives to improve ALS literacy.
    Keywords:  ALS awareness; Amyotrophic lateral sclerosis; Community survey; Cross-sectional study; Northern Border Region; Public knowledge; Saudi Arabia
    DOI:  https://doi.org/10.7717/peerj.21710
  54. bioRxiv. 2026 Oct 20. pii: 2026.10.16.759728. [Epub ahead of print]
      Amyotrophic lateral sclerosis is a multifactorial, late-onset neurodegenerative disease with incompletely understood pathogenesis. Limited survival after symptom onset creates an urgent need for biomarkers to support diagnosis, prognosis, and patient stratification. MicroRNAs are among the candidate biomarkers investigated in this disease. Although reviews have synthesized microRNA expression findings, differences in patient populations, biospecimens, and methods complicate comparisons. In the age of data-driven research, we need an updated, searchable resource that links each finding to its context and incorporates growing evidence. Here, we present ALSmiR, a public, manually curated database of polymerase chain reaction-based microRNA expression findings from human biological fluids and their components. ALSmiR currently contains 1,620 expression records from 49 publications comparing patients with amyotrophic lateral sclerosis with healthy controls, covering 816 microRNA names across 13 biospecimen categories. We link publication, cohort, and microRNA-result tables to preserve each finding's clinical and experimental context. We retain significant and non-significant results and provide searchable records and comma-separated values exports for independent analysis. We update ALSmiR annually and verify author submissions against source publications before inclusion. Researchers can use ALSmiR to assess candidate biomarkers, formulate hypotheses, and design independent validation studies. ALSmiR is freely accessible worldwide without registration at https://alsmir.dokhlab.org/ .
    DOI:  https://doi.org/10.64898/2026.10.16.759728
  55. Adv Pharm Bull. 2026 Sep;16(3): 655-664
       Purpose: Oxidative stress, edema, and blood-brain barrier (BBB) dysfunction are involved in the pathophysiology of stroke and may offer opportunities for managing its related insults. Sericin (Ser) has neuroprotective and pro-cognitive effects. This study aimed to determine whether Ser could reduce cerebral edema and its associated molecular and cognitive abnormalities in a mouse model of cortical ischemia.
    Methods: The mice were allocated into five cohorts: Sham, normal saline (NS), Ser200, Ser300, and Ser400. Each group received its treatment for 14 days before being subjected to cerebral ischemia or a sham surgery procedure. Spatial memory was assessed using the Lashley III maze. Brain edema, BBB permeability, malondialdehyde (MDA) level, and changes in anti-oxidant markers (total antioxidant capacity (TAC), as well as superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities) were evaluated in the brain samples. Additionally, the expression of BBB structural integrity proteins, including occludin and zonula occludens-1 (ZO-1), and matrix metalloproteinase-9 (MMP-9), were analyzed.
    Results: Ser300 and Ser400 improved spatial memory (at least P<0.05). Also, Ser400 reduced brain water content (P<0.05), Ser300 and 400 decreased BBB leakage (at least P<0.05), and normalized anti-oxidant markers (at least P<0.05). As well, Ser400 diminished MDA content (P<0.05). All doses decreased MMP-9 levels (at least P<0.01). Ser400 upregulated the expression of occludin (P<0.01), and Ser300 and 400 increased ZO-1 proteins (at least P<0.05).
    Conclusion: Ser improved cognitive dysfunction associated with BBB damage and edema induced by cerebral ischemia in a mouse model.
    Keywords:  Blood-brain barrier; Brain edema; Memory; Oxidative stress; Photothrombotic stroke; Sericin
    DOI:  https://doi.org/10.34172/apb.46668
  56. Malawi Med J. 2026 Feb;37(5): 71-77
       Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with metabolic abnormalities. Serum biomarkers such as uric acid (UA), homocysteine (Hcy), and cystatin C (Cys-C) may be involved in its pathogenesis and progression.
    Objective: To evaluate the associations between serum UA, Hcy, and Cys-C levels and disease duration, severity, and cognitive function in patients with PD.
    Methods: From January 2023 to December 2024, sixty patients diagnosed with PD and sixty age- and sex-matched healthy controls were enrolled. PD patients were further stratified by disease duration (<5 years vs. ≥5 years), Hoehn and Yahr (H&Y) stage (mild vs. moderate-to-severe), and Montreal Cognitive Assessment (MoCA) score (normal cognition vs. cognitive impairment). Serum levels of UA, Hcy, and Cys-C were compared among groups, and Pearson correlation analysis was performed to examine their relationships with disease duration, H&Y stage, and MoCA score.
    Results: Compared with healthy controls, PD patients exhibited significantly higher serum Hcy and Cys-C levels and lower UA levels (all P<0.01). Patients with longer disease duration, higher H&Y stage, or cognitive impairment showed elevated Hcy and Cys-C levels and reduced UA levels (P<0.01 for all comparisons). Pearson correlation analysis revealed that UA was negatively correlated with disease duration (r = -0.757, P<0.001), H&Y stage (r = -0.869, P<0.001), and MoCA score (r = -0.606, P<0.001), while Hcy and Cys-C were positively correlated with these indicators (all P<0.01).
    Conclusion: Elevated serum Hcy and Cys-C and reduced UA levels are closely associated with PD progression and cognitive decline. These biomarkers may serve as valuable indicators for monitoring disease severity and guiding clinical management.
    Keywords:  Hoehn and Yahr; Parkinson's disease; cognitive function; cystatin C; disease duration; homocysteine; serum uric acid
    DOI:  https://doi.org/10.4314/mmj.v37i5.12
  57. Sensors (Basel). 2026 Oct 30. pii: 6893. [Epub ahead of print]26(21):
      This systematic review and meta-analysis aimed to evaluate the performance of deep learning (DL)-based methods for classifying individuals with Parkinson's disease (PD) from handwriting and drawing tasks, following PRISMA guidelines. Google Scholar, IEEE Xplore, PubMed/MEDLINE, ScienceDirect, and Science.gov were searched from 1 July to 17 July 2026, without publication date restrictions. Eligible studies evaluated a DL architecture for PD detection using handwriting or drawing and reported at least one of five performance metrics: accuracy, sensitivity, specificity, precision, or F1-score. Two reviewers independently performed study selection, data extraction, and risk-of-bias assessment using PROBAST+AI. Performance estimates were logit-transformed and pooled separately using random-effects models. Heterogeneity was assessed using Cochran's Q, I2, and τ2, and results were presented using forest plots with 95% confidence intervals. Potential sources of heterogeneity were investigated through subgroup analyses according to DL architecture, dataset, task, and validation procedure, together with sensitivity analyses. Publication bias was assessed using Egger's test, and certainty of evidence was evaluated using GRADE. Of 5233 unique records identified, 30 studies were included. Overall pooled performance exceeded 92% across the evaluated metrics. No significant differences were found between fully DL and hybrid approaches or among DL algorithms. Dataset-related differences were observed but were inconsistent across performance metrics. Combined handwriting and drawing tasks consistently achieved higher performance (>95%) than individual tasks, while cross-validation was associated with higher accuracy, specificity, and sensitivity than hold-out validation. Despite these promising findings, substantial heterogeneity and very low certainty of evidence limit the current clinical applicability of these approaches. More standardized protocols, subject-level data separation, and external validation in independent populations are needed to develop robust and generalizable AI models and clarify the potential of handwriting and drawing as non-invasive tools for PD detection.
    Keywords:  Parkinson-disease assessment; accuracy; deep learning; level of evidence; logit transformation; meta-analysis; publication bias; risk of bias; sensors
    DOI:  https://doi.org/10.3390/s26216893
  58. Neuron. 2026 Nov 11. pii: S0896-6273(26)00810-X. [Epub ahead of print]114(21): 3984-4008
      Diseases of the central nervous system remain among the greatest unmet medical challenges. Human brain organoids provide 3D multicellular systems for investigating neurodevelopmental, infectious, and neurodegenerative diseases in a human cellular context. Considering these distinct disease areas together highlights how organoid studies are moving beyond recapitulating disease phenotypes to define molecular and cellular mechanisms and trajectories: when pathogenic changes emerge, how they evolve, which cell types and states drive or resist disease, and how multicellular interactions shape progression. Integrating human genetics with longitudinal, single-cell, multi-omic, and functional analyses provides access to human-specific processes that are difficult to capture in animal models and enables identification of mechanisms and therapeutic targets anchored in human disease biology. Increasingly, well-characterized organoids offer human new approach methodologies (NAMs) for preclinical therapeutic evaluation. Advances in reproducibility, benchmarking, and appropriate validation will be critical to establishing their predictive value and supporting their use in drug development and regulatory applications.
    Keywords:  autism; brain development; brain infection; neural organoids; neural stem cells; neurodegeneration; neurodevelopmental disorder; organoids; schizophrenia
    DOI:  https://doi.org/10.1016/j.neuron.2026.10.014
  59. Mol Med Rep. 2027 Jan;pii: 11. [Epub ahead of print]35(1):
      Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the accumulation of misfolded α‑synuclein forming Lewy bodies. Emerging evidence highlights mitochondrial dysfunction as an important and early event in PD pathogenesis. Among the key regulators of mitochondrial quality control, PTEN‑induced kinase 1 (PINK1) plays a pivotal role by initiating mitophagy, the selective clearance of damaged mitochondria. Under physiological conditions, PINK1 is rapidly degraded, whereas mitochondrial depolarization stabilizes PINK1 on the outer mitochondrial membrane, where it recruits and activates Parkin, an E3 ubiquitin ligase, to promote mitophagy. Loss‑of‑function mutations in PINK1 also disrupt this process, leading to the accumulation of dysfunctional mitochondria, oxidative stress, abnormal calcium homeostasis and neuronal apoptosis. Furthermore, PINK1 deficiency has been shown to exacerbate α‑synuclein aggregation, impair synaptic transmission and activate neuroinflammatory pathways, collectively accelerating dopaminergic neurodegeneration. Therapeutic strategies aimed at restoring or enhancing PINK1‑mediated mitophagy through pharmacological activation, gene delivery or modulation of parallel pathways‑represent a promising avenue for PD intervention. Continued elucidation of the molecular functions of PINK1 will provide critical insights into mitochondrial homeostasis and novel therapeutic targets for PD.
    Keywords:  PINK1; Parkinson's disease; mitochondrial autophagy
    DOI:  https://doi.org/10.3892/mmr.2026.14069
  60. Yale J Biol Med. 2026 Sep;99(3): 521-539
      Mitochondrial dysfunction is increasingly recognized as a shared mechanism across neurological disease. Specifically, impaired oxidative phosphorylation, oxidative stress, and mitochondrial DNA damage are factors in primary mitochondrial disorders and major neurodegenerative diseases such as Parkinson, Alzheimer, and Huntington diseases, and amyotrophic lateral sclerosis. This review surveys the mechanisms driving mitochondrial dysfunction and evaluates the current landscape of gene-editing technologies developed to address them. We examine mitochondria-targeted editors and nuclear-targeted editors, examining the editing capability, delivery constraints, and off-target risk of each. Heteroplasmy-shifting nucleases currently offer the strongest in vivo evidence for mtDNA-directed therapy, while base editors extend correction to homoplasmic mutations at the cost of a narrower editing scope and off-target editing. Nuclear editing platforms avoid the mitochondrial gRNA import barrier entirely, allowing current technologies to achieve the most progress toward functional, behavioral rescue in animal models. Across all platforms, delivery efficiency, off-target specificity, and translation from rodent to primate models remain unresolved barriers to clinical application. Gene editing for mitochondrial dysfunction is highly creditable as a precision therapy for genetically defined disease subsets, including primary mitochondrial disease and other neurodegenerative disorders with a known nuclear driver, rather than as a universal strategy for sporadic neurodegeneration, where mitochondrial dysfunction arises from multifactorial and poorly localized causes.
    Keywords:  Adeno-Associated Virus; Base Editing; CRISPR-Cas9; Gene Editing; Mitochondrial DNA; Mitochondrial Dysfunction; Neurodegenerative Disease; Nuclear DNA; Oxidative Phosphorylation; Reactive Oxygen Species
    DOI:  https://doi.org/10.59249/AFKC3347
  61. Pharmacol Res. 2026 Nov 11. pii: S1043-6618(26)01667-1. [Epub ahead of print] 109752
      Our society is aging. Accordingly, the incidence and prevalence of age-associated diseases are exponentially increasing. Among these diseases, neurodegenerative disorders emerge as major contributors to decreased health span. The molecular mechanisms underlying these disorders are complex and multifaceted. However, increased generation of reactive oxygen species (ROS) and associated oxidative stress have emerged as a potent contributor to the etiopathology of many of these disorders, including Alzheimer's Disease and Parkinson's Disease (AD and PD, respectively). In this context, changes in copper homeostasis have been described as important contributors to increased ROS generation and associated oxidative stress, and targeting Cu homeostasis has been explored as a promising pharmacological approach. In this bibliographical review, we comprehensively discuss the most relevant pharmacological approaches in the field. Most of the research articles discussed here used AD and PD models, but some studies also employed models of less common neurodegenerative disorders. The literature presented here demonstrates the promising effects of targeting Cu homeostasis to halt increased ROS generation and associated oxidative stress in neurodegenerative disorders. However, many of these studies were conducted in vitro, with only a small portion in murine models of the diseases. Consequently, further research is needed to determine whether the promising results are, in fact, translatable to human therapeutics. The urgency for these studies is real, considering the high incidence and prevalence of neurodegenerative disorders and the limited therapeutics in the field.
    Keywords:  Alzheimer’s disease; Parkinson’s disease; copper; mitochondria; mitochondrial dysfunction; neurodegenerative disorders; oxidative stress; reactive oxygen species
    DOI:  https://doi.org/10.1016/j.phrs.2026.109752
  62. Eur J Transl Myol. 2026 Nov 13.
      Oropharyngeal Dysphagia (OD) is a prevalent and potentially life-threatening complication of Neuromuscular Disorders (NMDs). Tongue ultrasonography is an inexpensive, non-ionising, point-of-care technique that permits quantitative assessment of lingual muscle structure, but its value as a biomarker of OD across NMDs has not been systematically appraised. This systematic review aims to synthesize the available evidence on the diagnostic accuracy, reliability and clinical utility of quantitative tongue ultrasonography as a biomarker of OD in adults with NMDs. We systematically searched PubMed and Scopus for studies correlating quantitative tongue-ultrasound parameters, Tongue Thickness (TT) or Echo Intensity (EI), with instrumental swallowing assessment in adults with NMDs, following the PRISMA 2020 guideline. Study selection, data extraction and risk-of-bias appraisal were performed independently by two reviewers. Six studies (n = 10-38 per cohort) met the inclusion criteria. Reduced TT was a consistent marker of lingual atrophy in Amyotrophic Lateral Sclerosis (ALS) and correlated with oral-phase swallowing impairment, whereas functional measures of tongue strength were stronger predictors of aspiration risk. In Duchenne Muscular Dystrophy (DMD), increased TT reflected "pseudohypertrophy" from fatty and connective-tissue infiltration rather than preserved function and EI provided a complementary index of tissue quality in myopathic NMDs. Tongue ultrasonography is a promising, disease-sensitive biomarker for monitoring bulbar dysfunction in NMDs, but morphological indices should be integrated with functional swallowing data to predict aspiration risk. Standardized acquisition protocols and larger, longitudinal, multicentre studies are required before clinical implementation.
    Keywords:  Rehabilitation; Oropharyngeal dysphagia; Ultrasonography; Neuromuscular disorders; Swallowing dysfunction.
    DOI:  https://doi.org/10.4081/ejtm.2026.16288
  63. J Ethnopharmacol. 2026 Nov 07. pii: S0378-8741(26)01467-4. [Epub ahead of print]375(Pt A): 122612
       ETHNOPHARMACOLOGICAL RELEVANCE: Astragalus membranaceus (Fisch.) Bunge (Fabaceae) is documented in Shennong's Classic of Materia Medica to treat Qi deficiency-induced cerebral blood stasis and limb tremor resembling Parkinson's disease (PD). Its primary bioactive component, calycosin (CA), exerts anti-ferroptosis effects; however, its ability to cross the blood-brain barrier (BBB) is severely limited. Herbal-derived exosomes isolated from Astragalus membranaceus act as homologous natural nanocarriers to overcome this limitation; however, the anti-PD efficacy and nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent ferroptosis regulatory mechanism of Astragalus membranaceus-derived exosomes (AS-Exos) loaded with CA (AS-Exos-CA) remain unelucidated.
    AIM OF THE STUDY: To construct AS-Exos-CA, verify both its BBB-crossing capacity and neuroprotective effect on dopaminergic neurons, and investigate whether its anti-ferroptosis protection relies on the Nrf2/SLC7A11/GPX4 axis, to provide modern pharmacological evidence for the ethnopharmacological application of Astragalus membranaceus against PD.
    MATERIALS AND METHODS: AS-Exos were isolated by ultracentrifugation and characterized using NTA and TEM. HPLC was employed to screen the optimal CA-loading ratio for preparing AS-Exos-CA and measure its encapsulation efficiency. PKH26 and DiR fluorescence labeling were used to assess cellular uptake and BBB penetration of AS-Exos-CA in PC12 cells and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice, respectively. Motor function, dopaminergic neuron survival, ferroptosis-related oxidative stress, iron metabolism and mitochondrial ultrastructure were assessed to evaluate the therapeutic effects of AS-Exos-CA in MPTP-induced PD mice. 1-methyl-4-phenylpyridinium ion (MPP+)-injured PC12 cells combined with the Nrf2-specific inhibitor ML385 were used to verify the Nrf2-dependent mechanism mediating AS-Exos-CA-derived protection.
    RESULTS: AS-Exos-CA displayed typical vesicle morphology, was efficiently taken up by PC12 cells, and significantly accumulated in mouse brain 12 h after intravenous injection. Compared with free CA and AS-Exos, AS-Exos-CA more effectively ameliorated motor deficits, rescued dopaminergic neurons, mitigated mitochondrial injury and iron deposition, restored glutathione (GSH), and lowered malondialdehyde (MDA) and reactive oxygen species (ROS) levels. AS-Exos-CA facilitated Nrf2 nuclear translocation and up-regulated the downstream expression of SLC7A11 and GPX4. ML385 abolished its in vitro anti-ferroptotic actions, verifying the essential role of Nrf2 signaling.
    CONCLUSION: AS-Exos serve as homologous herbal nanocarriers, enhancing CA penetration across the BBB for brain delivery. AS-Exos-CA exerts robust neuroprotection against PD largely by inhibiting neuronal ferroptosis via the Nrf2/SLC7A11/GPX4 pathway. This herbal exosome-based nanoformulation overcomes the biocompatibility limitations of synthetic nanomaterials and represents a promising disease-modifying strategy for PD, thereby advancing the modern investigation of Qi-tonifying herbal medicines in degenerative central nervous system (CNS) disorders.
    Keywords:  Astragalus membranaceus; Blood-brain barrier; Calycosin; Ferroptosis; Herbal-derived exosomes; Nrf2/SLC7A11/GPX4 axis; Parkinson's disease
    DOI:  https://doi.org/10.1016/j.jep.2026.122612
  64. Transl Neurodegener. 2026 Nov 09. pii: 60. [Epub ahead of print]15(1):
      Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) show significant differences in their clinical manifestations, but they all seem to share a common upstream problem: malfunction in the membrane transport controlled by Rab GTPases. This review introduces the concept of Rabopathy, a framework that connects developmental synaptic maturation defects with late-onset protein aggregation. The LRRK2-Rab phosphorylation axis is emerging as a potential common amplifying mechanism across these disorders, with the strongest mechanistic support in PD and growing implications in AD and HD. When Rab substrates are excessively phosphorylated at specific sites, vesicular transport is impaired or arrested, leading to progressive depletion of the reserve pool of synaptic vesicles and the surface pool of receptors, and severe compromise of the autophagy-lysosome flux. The failure of distinct Rab sub-networks also produces disease-specific signatures, including Rab5-driven endosomal congestion in AD, Rab35-mediated α-synuclein secretion in PD, and Rab11/Rab7 trafficking collapse in HD. Restoration of Rab flux may be a therapeutic strategy for neurodegenerative diseases, which can be achieved through calibration of LRRK2 activity, modulation of selective Rab subtypes, and rescue of the trafficking network at the systems level.
    Keywords:  Autophagy-lysosome pathway; LRRK2; Membrane trafficking; Neurodegeneration; RAB39B; Rab GTPases; Rabopathy
    DOI:  https://doi.org/10.1186/s40035-026-00596-8
  65. Int J Mol Sci. 2026 Nov 05. pii: 9926. [Epub ahead of print]27(21):
      Neurodegenerative diseases are a growing global health burden associated with aging and characterized by progressive neuronal dysfunction, metabolic failure, mitochondrial impairment, oxidative stress, and chronic neuroinflammation. Among the metabolic pathways implicated in these disorders, coenzyme A (CoA)-linked biology has emerged as a potentially important but still underexplored contributor to neuronal resilience and vulnerability. Pantethine, a disulfide derivative of pantetheine and a CoA-related metabolic precursor, has attracted attention because of its reported effects on cellular metabolism, redox balance, and inflammatory signaling. However, its relevance across neurodegenerative diseases remains unevenly defined, with direct support strongest in pantothenate kinase-associated neurodegeneration (PKAN) and more limited evidence in common disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). This narrative review critically examines the mechanistic and translational evidence linking pantethine to neurodegeneration. PKAN represents the most logical disease context for pantethine investigation because impaired CoA biosynthesis is proximal to disease pathogenesis, although pantethine remains investigational and its clinical efficacy has not been established. By contrast, proposed applications in AD and PD remain highly theoretical and hypothesis-generating. Nevertheless, research on pantethine and related CoA-restoring strategies may identify new intervention targets across neurodegenerative diseases and other disorders characterized by impaired cellular bioenergetics, including selected neuropsychiatric disorders. These possibilities require biomarker-informed, disease-specific studies that establish active-species exposure, target engagement, and clinically meaningful effects.
    Keywords:  Alzheimer’s disease; Parkinson’s disease; coenzyme A; glial cells; kynurenine; mitochondrial dysfunction; neurodegeneration; neuroinflammation; oxidative stress; pantethine; pantothenate kinase-associated neurodegeneration (PKAN)
    DOI:  https://doi.org/10.3390/ijms27219926
  66. Curr Opin Neurol. 2026 Dec 01. 39(6): 586-596
       PURPOSE OF REVIEW: Drug delivery across the blood-brain barrier (BBB) remains an important challenge in the treatment of brain tumors. This review summarizes the physiologic barriers to effective CNS drug exposure and evaluates strategies to improve delivery, with a focus on glioma.
    RECENT FINDINGS: Recent advances span three complementary approaches: engineering therapeutics for BBB penetration, transient BBB disruption, and locoregional delivery to bypass the BBB. Modern medicinal chemistry has enabled highly brain-penetrant agents such as vorasidenib, while transporter/receptor-mediated and nanocarrier platforms remain under investigation. Ultrasound with microbubbles has emerged as a leading strategy for spatially targeted, reversible BBB disruption, with early clinical studies demonstrating increased delivery of chemotherapies and monoclonal antibodies. Convection-enhanced delivery has benefited from improved catheter design, image guidance, and implantable systems, although efficacy in brain tumors remains unproven. Intratumoral oncolytic viruses and CSF-based cellular therapies are additional emerging approaches.
    SUMMARY: Strategies for drug delivery to brain tumors have advanced substantially, but translation remains challenging. Efficacious therapies must not only overcome the BBB but also achieve adequate exposure and target engagement across heterogeneous tumor regions. Future studies must pair active therapeutics with relevant delivery strategies, ascertain drug exposure and target engagement early through window-of-opportunity studies, and evaluate efficacy in randomized trials.
    Keywords:  blood–brain barrier; drug delivery; focused ultrasound
    DOI:  https://doi.org/10.1097/WCO.0000000000001521
  67. RSC Adv. 2026 Nov 10.
      The blood-brain barrier (BBB) remains a major obstacle to central nervous system drug delivery. Receptor-mediated transcytosis offers a promising strategy, motivating diverse molecular shuttle designs. Here, we systematically analyse 563 chemically defined BBB shuttles, comprising peptides (229), aptamers (149), antibodies (114), nanobodies (11), primary nanoparticles (12), and other constructs (48). Despite extensive chemical diversity, documented advanced-stage evidence remains concentrated in relatively few constructs. In the originally annotated subset (356/563 shuttles), only 39 reached the level indicating quantitative in vivo brain exposure or functional CNS delivery. Antibodies accounted for 71.8% (28/39) of these records, compared with 28.2% (11/39) for peptides and aptamers combined. Transferrin receptor dominated aptamer targeting (71.8%), whereas neonatal Fc receptor predominated among peptides (73.4%). The 39 advanced-stage records represented only seven annotated receptor targets. These findings reveal a disconnect between molecular diversification and documented translational evidence for BBB shuttles in our dataset. Further progress requires rigorous quantification of brain delivery, improved mechanistic validation, and systematic optimisation of receptor engagement, trafficking, molecular design, and cargo release.
    DOI:  https://doi.org/10.1039/d6ra08288b
  68. Front Microbiol. 2026 ;17 1984969
      Enterovirus A71 (EV-A71) is an important cause of severe neurological complications of hand, foot, and mouth disease in children. Most infections remain confined to peripheral sites, whereas only a small proportion progress to central nervous system (CNS) disease, and the mechanisms underlying this transition remain incompletely understood. Here, we reappraise EV-A71 neuropathogenesis as a multistage process comprising peripheral replication, systemic dissemination, CNS entry, establishment of productive CNS infection, and subsequent tissue injury. This distinction is important because these events are mechanistically connected but not interchangeable. Current evidence supports both neurovascular and peripheral neural routes of CNS entry, although the nature and strength of the supporting evidence differ. Human-derived blood-brain barrier (BBB) models demonstrate that EV-A71 and virus-associated carriers can engage and cross neurovascular interfaces, whereas temporal studies in animals, perturbation of axonal transport, and compartmentalized neuronal models provide stronger causal support for retrograde axonal transport once the virus has accessed peripheral nerves. These findings establish mechanistic feasibility, but the timing, necessity, and relative contribution of each route during natural infection in children remain unresolved. We further emphasize that BBB crossing is not synonymous with BBB disruption, and that CNS entry does not necessarily result in productive CNS infection. On this basis, we propose a multistage progression-constraint model, in which progression to severe neurological disease requires EV-A71 to overcome distinct constraints imposed by tissue context, viral properties, and host factors at successive stages. This framework provides a testable explanation for why most infections remain peripheral while only a minority progress to severe neurological disease, and highlights the need for longitudinal clinical studies and directly comparable experimental models to identify where disease trajectories first diverge.
    Keywords:  blood–brain barrier; enterovirus A71; multistage progression constraints; neuroinvasion; neurotropism; retrograde axonal transport; systemic dissemination
    DOI:  https://doi.org/10.3389/fmicb.2026.1984969
  69. Physiol Rev. 2026 Nov 09.
      Neuromelanins (NMs) accumulate in large amounts in catecholaminergic neurons of the substantia nigra (SN) and locus coeruleus (LC), which selectively degenerate in Parkinson's disease (PD) and Alzheimer's disease (AD). Lower amounts of NMs are also present in other human brain regions. NMs are contained in specialized autolysosomes with lipid bodies, proteins, and metals. Their structure, synthesis, functions, and cellular localization differ from those of melanins in non-nervous tissues. Purified NMs have a complex structure, are composed of melanic moieties, lipids, proteins, and inorganic components, and are insoluble. NMs can exert either a protective or toxic role depending on cellular context. NMs synthesis is driven by cytosolic catecholamines and is a protective process, as it removes excess cytosolic catechols that would otherwise trigger neurotoxicity. NMs can bind reactive/toxic metals, forming stable and non-toxic complexes, thereby playing a neuroprotective role. However, NMs released from degenerating neurons in PD and AD activate microglia, which release reactive species and proinflammatory factors, thereby exacerbating neuroinflammation and neurodegeneration. The major histocompatibility complex class I is present within NM-containing organelles of SN and LC neurons and can bind antigens, presenting them on the neuronal membrane. Subsequently, CD8+ T-cells may target catecholaminergic NM-containing neurons, contributing to neurodegeneration. The loss of NM-containing neurons in PD and AD causes a decrease of NMs concentration within the SN and LC, which can be visualized using magnetic resonance imaging (MRI). NM-sensitive MRI of the SN and LC is increasingly being used for the diagnosis and treatment monitoring of neurodegenerative and psychiatric disorders.
    Keywords:  brain aging; metals; neurodegenerative diseases; neuroinflammation; neuromelanins
    DOI:  https://doi.org/10.1152/physrev.00036.2025
  70. bioRxiv. 2026 Oct 14. pii: 2026.10.13.755334. [Epub ahead of print]
      Amyotrophic lateral sclerosis (ALS) is a complex and heterogenous disease, comprising of familial and sporadic forms, numerous genetic mutations, and a wide range of affected cell types and proposed dysregulated processes. While the usage of in vitro cell cultures, mouse models, and postmortem patient tissue have advanced our understanding of ALS disease mechanisms, the temporal progression of the disease and how early molecular changes evolve remain poorly understood. Here, we establish human spinal cord organoids (hSpO) derived from C9orf72 patient induced pluripotent stem cells (C9-ALS hiPSCs) as a platform to model longitudinal changes across the disease trajectory. We show that C9-ALS hSpO recapitulate hallmark C9orf72 -related pathologies, increased cell death, and progressive neuronal dysfunction. We further identify RNA splicing dysregulation as an early and persistent feature of C9-ALS, with splicing signatures in hSpO closely mirroring those observed in postmortem patient tissue. Finally, prediction of RNA binding proteins (RBPs) that induce early splicing changes in C9-ALS reveals signatures consistent with a broad RBP network dysfunction. Together, this work establishes hSpO as an in vitro system for investigating early disease mechanisms of ALS in a human multicellular context and highlights dysregulated events that precede cell death.
    DOI:  https://doi.org/10.64898/2026.10.13.755334
  71. J Cell Biol. 2027 Jan 04. pii: e202505164. [Epub ahead of print]226(1):
      Parkinson's disease (PD) is marked by progressive dopamine neuron degeneration, but the phagocytic receptors and cells that clear neuronal corpses remain ill-defined. Moreover, while other cell types like glia, epithelia, and muscle are also impacted in PD, their roles in disease progression are unclear. We report that multiple nonneuronal cell types modulate dopamine neurodegeneration in Caenorhabditis elegans. Astrocyte-like CEPsh glia respond to neuronal stress and regulate dopamine biosynthesis enzyme CAT-2/TH and transporter DAT-1/SLC6A3. They are neurotoxic by downregulating neuroprotective dopamine levels. Degenerating dopamine neurons expose phosphatidylserine (PS) via the necrotic phospholipid scramblase ANOH-1/TMEM16F and ABC transporter CED-7/ABCA1. Epithelia and muscle cells then phagocytose dopamine neuron corpses and drive neuron death and clearance via the conserved PS receptor CED-1/Draper/MEGF10. Depleting ced-1 protects against loss of dopamine neurons and associated animal behaviors in a PD model. Evolutionary conservation of the underlying components and their effects across PD models suggests that multi-organ engagement may be a shared feature of dopamine neurodegeneration in PD.
    DOI:  https://doi.org/10.1083/jcb.202505164
  72. J Pharmacol Sci. 2026 Dec;pii: S1347-8613(26)00059-9. [Epub ahead of print]162(4): 307-318
      Predicting drug permeability through the blood-brain barrier (BBB) is important for developing pharmaceuticals for the central nervous system. In this study, we evaluated whether cryopreservation affects the molecular characteristics of human induced pluripotent stem cell-derived brain microvascular endothelial cells (iBMECs) using proteomic analysis. Cryopreserved iBMECs (Cryo-iBMECs) were compared with freshly differentiated iBMECs to assess global protein expression profiles and functional characteristics. Proteomic analysis revealed a strong correlation in protein expression between iBMECs and Cryo-iBMECs (Pearson's correlation coefficient r = 0.969). We further investigated whether the permeability properties of drugs in Cryo-iBMECs correlated with in vivo drug distribution. The permeability values obtained in Cryo-iBMECs were compared with reported in vivo values in mice, rats, cynomolgus monkeys, and humans. The results indicated that apparent permeability coefficients (Papp) values in Cryo-iBMECs were highly correlated with in vivo data in humans and cynomolgus monkeys. These findings indicate that Cryo-iBMECs retain key molecular characteristics and may serve as a practical in vitro platform for evaluating human BBB drug permeability.
    Keywords:  Blood-brain barrier; Cryopreservation; Drug permeability; K(p,uu,CSF); iPSC-derived brain microvascular endothelial cell
    DOI:  https://doi.org/10.1016/j.jphs.2026.10.003
  73. Mater Today Bio. 2026 Dec;41 103789
      Alzheimer's disease (AD) is an irreversible neurodegenerative disease that has thus far suffered from unsatisfactory therapeutic outcomes. Despite ongoing research into AD pathogenesis and related drugs, few disease-modifying therapies are currently available. Moreover, efficient drug delivery is significantly hindered by low permeability of the blood-brain barrier (BBB) and non-specific distribution within the brain, further limiting the efficacy of existing anti-AD medications. Nanotechnology has recently emerged as a promising approach to overcome these challenges. This review aims to offer a comprehensive overview of recent advances in precision nanoparticle-based drug delivery systems for AD therapy. First, we outline the multiple pathological mechanisms and representative pathogenesis-inspired therapies of AD. Next, we summarize various types of nanoparticles that have been utilized in AD drug delivery, including polymeric, lipid-based, inorganic, and biomimetic nanocarriers. Subsequently, we highlight the nanoparticle-mediated strategies for cascaded precision drug delivery at different levels, focusing on both the BBB and specific pathologies or cell populations within AD lesions. Finally, we discuss potential challenges and prospects in employing precision delivery systems, aiming to accelerate the development and clinical translation of nanoparticle-based therapies for AD.
    Keywords:  Alzheimer's disease; Blood-brain barrier; Disease-modifying therapy; Nanoparticles; Nanotechnology; Precision drug delivery
    DOI:  https://doi.org/10.1016/j.mtbio.2026.103789
  74. Discov Nano. 2026 Nov 10. pii: 613. [Epub ahead of print]21(1):
      Efficiently delivering therapeutics to the central nervous system (CNS) remains a major challenge in multiple sclerosis (MS), particularly for strategies targeting CNS-resident pathology, neuroprotection, or remyelination. This review provides a delivery- and formulation-centered comparative analysis of CNS drug delivery strategies for MS, integrating administration route, nanocarrier design, evidence level, and translational feasibility within a unified framework. A structured narrative review was conducted using literature identified through PubMed, Scopus, and Google Scholar, encompassing conventional and alternative administration routes, including intranasal (IN) delivery, and lipid-based, polymeric, and hybrid nanocarrier systems. Strategies were evaluated using predefined criteria, including BBB permeability or CNS exposure, targeting capability, bioavailability, formulation characteristics, and translational feasibility. A semi-quantitative heatmap based on a predefined ordinal scoring system and available experimental and clinical evidence was developed to enable transparent comparison. Conventional systemic administration may be limited by systemic exposure, first-pass metabolism, and restricted CNS access. IN administration is a promising investigational approach to enhance CNS exposure for selected compounds; however, evidence for direct nose-to-brain (N2B) transport depends on the drug, formulation, and experimental model. Nanocarriers can improve solubility and stability, protect against degradation, enable controlled release, and may enhance CNS exposure or cellular targeting in selected preclinical settings. Nevertheless, evidence for BBB penetration, direct CNS targeting, and therapeutic efficacy remains predominantly preclinical, with limited standardized pharmacokinetic and clinical validation. Overall, the comparative framework highlights the importance of jointly considering administration route, nanocarrier properties, and evidence maturity to guide rational CNS delivery design and future translational development in MS.
    Keywords:  Blood–brain barrier; CNS targeting; Intranasal delivery; Multiple sclerosis; Nanocarriers; Nanomedicine; Nanotechnology; Nose-to-brain transport; Surface-functionalized nanoparticles
    DOI:  https://doi.org/10.1186/s11671-026-05118-z